Physiol Rev 84: 623– 647, 2004; 10.1152/physrev.00032.2003. Mouse Models of Insulin Resistance ANINDITA NANDI, YUKARI KITAMURA, C. RONALD KAHN, AND DOMENICO ACCILI Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York; and Joslin Diabetes Center, Harvard University Medical School, Boston, Massachusetts 624 624 625 626 626 627 628 629 629 629 630 630 631 631 632 633 633 633 633 633 634 634 634 634 634 635 635 635 635 635 636 636 636 Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 I. Introduction II. Overview of Insulin Action III. Insulin Receptor Knockout A. Insulin receptor’s growth effects B. Metabolic effects IV. Conditional Mutagenesis of Insulin Receptor A. Skeletal muscle B. Heart C. Adipose tissue D. Brown adipocyte E. Hepatocytes F. Vascular endothelium G. Neurons H. Pancreatic -cell I. What is the role of insulin signaling in pancreatic -cells? V. Igfr1 Knockout VI. Insulin Resistance Caused by Mutations of Genes Encoding Proteins in the Insulin Signaling Pathway A. Irs signaling B. Irs1 knockout C. Irs2 knockout D. Irs3 knockout E. Irs4 knockout VII. Double Irs Gene Knockouts A. Irs1 and Irs2 B. Irs1 and Irs3 C. Irs1 and Irs4 D. Akt E. Glut4 F. Heart-specific Glut4 ablation G. Muscle-specific Glut4 ablation H. Fat-specific Glut4 ablation I. Genes in the Glut4 translocation pathway: syntaxin4 J. Ceacam1 and insulin clearance VIII. Mixing and Matching: Modeling the Complex Genetics of Type 2 Diabetes Through Experimental Mouse Crosses A. Insr haploinsufficiency and diabetes IX. Gene Knockouts Associated With Increased Insulin Sensitivity A. Protein tyrosine phosphatase B. PI3K regulatory subunits C. Ship2 D. c-Jun amino-terminal kinase E. Salicylates, Ikk, and the metabolic syndrome F. The forkhead transcription factor Foxo1 X. Conclusions 636 636 637 638 638 638 638 639 639 640 Nandi, Anindita, Yukari Kitamura, C. Ronald Kahn, and Domenico Accili. Mouse Models of Insulin Resistance. Physiol Rev 84: 623– 647, 2004; 10.1152/physrev.00032.2003.—Insulin resistance plays a key role in the pathogenesis of several human diseases, including diabetes, obesity, hypertension, and cardiovascular diseases. The predisposiwww.prv.org 0031-9333/⫺2000 $15.00 Copyright © 2004 the American Physiological Society 623 624 NANDI, KITAMURA, KAHN, AND ACCILI tion to insulin resistance results from genetic and environmental factors. The search for gene variants that predispose to insulin resistance has been thwarted by its genetically heterogeneous pathogenesis. However, using techniques of targeted mutagenesis and transgenesis in rodents, investigators have developed mouse models to test critical hypotheses on the pathogenesis of insulin resistance. Moreover, experimental crosses among mutant mice have shed light onto the polygenic nature of the interactions underlying this complex metabolic condition. I. INTRODUCTION TABLE II. OVERVIEW OF INSULIN ACTION Insulin acts through a cell surface receptor that belongs to a subfamily of growth factor receptor tyrosine kinases. This subfamily is comprised of three members: insulin receptor (Insr), type 1 insulin-like growth factor (IGF) receptor (Igf1r), and Insr-related receptor (Irr) (172, 209, 232, 233). Interestingly, although these receptors are highly conserved from a structural standpoint, their functions are quite distinct, with Insr being primarily important for fuel metabolism and Igf1r for growth. No clear-cut function has been ascribed thus far to Irr, in part because it is unable to bind any of the ligands that are known to activate the other two receptors: insulin, Igf1, and Igf2 (172). The three receptors also share common intracellular signaling pathways. There are two main pathways that 1. Summary of mutant mice described in text Gene Phenotype Reference Nos. Igf1r Muscle-targeted DN Igf1r -Cell Igf1r Irs1 Irs2 Irs3 Irs4 Irs1 ⫹ Irs2 Irs1 ⫹ Irs3 Irs1 ⫹ Irs4 Pi3kr (p85␣) Pan-Pi3kr Glut2 Glut4 Glut4⫹/⫺ Glut4 (heart specific) Glut4 (muscle specific) Glut4 (adipose specific) Syntaxin4 Ceacam Akt2 Ptp1b Ship2 Jnk2 Ikk Foxo1 Pkc  Impaired -cell growth Insulin-resistant diabetes Hyperinsulinemia, IGT Growth retardation, insulin resistance -Cell dysfunction None apparent Growth retardation, insulin resistance Embryonic lethality Lipoatrophy Growth retardation, insulin resistance Hypoglycemia Hypoglycemia Impaired insulin secretion, diabetes Cardiac hypertrophy Insulin resistance, diabetes Cardiac hypertrophy Insulin-resistant diabetes Insulin-resistant diabetes Insulin resistance Impaired insulin clearance Insulin resistance Resistance to diet-induced insulin resistance Hypoglycemia Increased insulin sensitivity Increased insulin sensitivity Increased insulin sensitivity Increased insulin sensitivity 241 63 135, 245 13, 221 242 154 62 165, 241 141 141 226 70 83 106 217 1 254 2 246 189 42 60, 124 43 91 250 123, 171, 173 214 Physiol Rev • VOL 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 Type 2 diabetes results from a combination of insulin resistance and impaired insulin secretion (203). The two abnormalities are intertwined, but in most individuals the onset of insulin resistance precedes overt -cell dysfunction and is thought to arise from genetic predisposition. Nonetheless, subclinical -cell dysfunction can be demonstrated in nondiabetic first-degree relatives of diabetic patients, consistent with the hypothesis that -cell failure is also genetically programmed (186). The predisposition to insulin resistance and/or -cell dysfunction is inherited in a non-Mendelian fashion (22), due to their genetic heterogeneity and multigenic pathogenesis. Moreover, environmental factors such as inappropriate diet and inactivity can modulate the manifestations of the genotype (incomplete penetrance) or mimic the genetic contribution, resulting in phenocopies (139). Thus human genetic studies of the predisposition to insulin resistance are fraught with uncertainties and complicated by the considerable variations of the human genetic pool. To dissect the complex genetics of insulin resistance and -cell dys- function, investigators have generated transgenic and knockout mice bearing mutations in genes required for insulin action and/or insulin secretion (Table 1). This review focuses on lessons learned from these mouse models. 625 INSULIN RESISTANCE IN MICE agents that mimic insulin’s effect to activate PI3K are unable to promote glucose transport, suggesting that PI3K may be necessary, but not sufficient, to promote glucose transporter translocation (98). Based on these observations, a new cascade emanating from Insr has been identified that leads to insulin stimulation of glucose transport in a PI3K-independent fashion. This pathway is based on the activation of the protooncogene c-Cbl (19, 41). There is evidence that this or a related pathway may lead to glucose transporter recycling via remodeling of cortical actin filaments within the cell (229), potentially involving atypical myosin isoforms (32, 99). III. INSULIN RECEPTOR KNOCKOUT The generation of mice bearing null Insr mutations has been instrumental to dissecting the pathogenesis of insulin resistance, diabetes, and growth retardation (4, 101). Mice lacking insulin receptors are born at term with slight growth retardation (⬃10%) (156). After birth, there is a progressive increase in glucose levels, accompanied by a transient, robust increase in insulin levels up to 1,000-fold above normal. However, -cell “failure” occurs within a few days, characterized by extensive degranulation of -cells (172) and followed by death of the animals in diabetic ketoacidosis. This phenotype indicates that Insr is necessary for postnatal fuel homeostasis, but not for prenatal growth and metabolic control. The Insr null mouse is remarkably different from humans carrying similar mutations (102, 131, 191, 222, 238). Unlike mice, humans lacking insulin receptors show severe intrauterine growth retardation, failure to thrive, FIG. 1. Protomechanics of insulin signaling. Insulin binding to the extracellular domain of the insulin receptor elicits a conformational change, which in turn leads to receptor autophosphorylation and tyrosine phosphorylation of intracellular protein substrates. Several branching pathways are activated by insulin: the Irs pathway leads to generation of tris-phosphorylated inositol, activation of phosphatidylinositol trisphosphate (PIP3)-dependent serine/threonine kinases such as Akt and Sgk, and modulation of enzyme activities. The Grb2/SOS pathway leads to activation of Ras signaling, affecting cell proliferation, nutrient sensing, and gene expression. The protooncogene Cbl activates the Crk/TC-10 pathway, leading to glucose transporter translocation by way of a phosphatidylinositol 3-kinase (PI3K)-independent pathway. Physiol Rev • VOL 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 propagate the signal generated through insulin and Igf1 receptors: the insulin receptor substrate (Irs) 3 phosphatidylinositol 3-kinase (PI3K) pathway (39), and the Ras 3 mitogen-activated protein (MAP) kinase pathway (111) (Fig. 1). The Irs 3 PI3K pathway leads to the activation of a cascade of PI3K-dependent kinases, such as Pdk1 (7). Pdk1, in turn, phosphorylates and activates additional serine/threonine kinases, the most prominent of which are the three Akt isoforms (37). Akt phosphorylates glycogen synthase kinase 3 (Gsk3) (47), cGMP-inhibitable phosphodiesterase 3b (121), and Foxo transcription factors (26, 33, 170), leading to stimulation of glycogen synthesis and inhibition of lipolysis and gene expression, respectively. There is also evidence linking Akt activation to stimulation of glucose transport (125, 126). In contrast, activation of protein kinase C (PKC) in response to insulin remains controversial. Interest in the role of this family of kinases has been rekindled by the observations that dominant negative inhibitors of its atypical isoforms results in partial inhibition of glucose uptake in adipocytes (130) and that increased PKC activity is associated with increased intramyocellular triglycerides, a hallmark of insulin resistance (249). Insulin also activates the Ras 3 MAP kinase pathway through the formation of complexes between the exchange factor Sos and Grb2 (212). Grb2 can be activated by Irs or Shc, two direct substrates of the Insr kinase. The emerging consensus is that the acute metabolic effects of insulin require activation of the Irs 3 PI3K pathway, whereas the Ras 3 MAP kinase pathway plays a role in certain tissues to stimulate the actions of insulin on growth and proliferation. This is an oversimplification. For example, whereas inhibition of PI3K can effectively blunt insulin action on glucose transport (210), 626 NANDI, KITAMURA, KAHN, AND ACCILI lipodystrophy, and hypoglycemia (93, 102, 103, 131, 191, 220, 223, 238). We examine the mechanism of these differences in the next three sections. A. Insulin Receptor’s Growth Effects Physiol Rev • VOL B. Metabolic Effects The development of diabetes in Ins or Insr null mice at an early postnatal stage suggests that an insulin-dependent fuel-sensing apparatus develops perinatally in rodents. This is an additional developmental difference with humans, in whom insulin responsiveness is established during the last trimester of gestation. Similar to Ins1/Ins2 and Insr knockouts, mutations in other key genes required for glucose metabolism give rise to early neonatal diabetes, for example, glucokinase (80, 188, 225), Glut2 (83), and Pepck (207), as well as genes encoding transcription factors required for insulin gene transcription and/or pancreatic -cell development (3). However, the most important and seemingly paradoxical difference between Insr-deficient mice and humans is that mice are steadily hyperglycemic, whereas humans develop postprandial hyperglycemia and fasting hypoglycemia. There is no direct demonstration of a mechanism that would explain this difference. However, some physiological considerations and a new mouse model can help us formulate an educated guess. In humans with INSR mutations, hypoglycemia develops dur- 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 Although the primary focus of this review is insulin resistance, the known correlation between birth weight and predisposition to diabetes indicates a complex interaction between metabolism and growth (48). The lack of significant growth retardation in Insr-deficient mice appears to be due to differences in developmental timing between humans and rodents, rather than to the absence of growth-promoting effects of insulin (156). Evidence for a role of Insr in promoting embryonic growth derives from studies of mice with combined mutations in various elements of the insulin/Igf system. These experiments indicate that Insr is the receptor that mediates Igf2’s effects on embryonic growth. Thus single mutations ablating Insr function result in embryos that are 90% of normal weight, while single Igf1r mutations result in small embryos (45% of normal). Combined ablation of Insr and Igf1r, however, results in smaller embryos than either mutation alone (30% of normal), suggesting that the two receptors have partially overlapping growth-promoting functions. The same extent of growth retardation (30% of normal weight) is associated with combined mutations of Igf1 and Igf2. Combined mutations inactivating Igf2 and Igf1r also result in 30% embryos, suggesting that Igf2 signals through both Igf1r and Insr. In contrast, double mutants of Igf1 and Igf1r have the same phenotype as single mutants of either gene, indicating that their functions are entirely overlapping in promoting embryonic growth. This genetic evidence indicates that Insr acts as an Igf2 receptor during embryogenesis. Biochemical evidence supports this conclusion. Insr is expressed as two alternatively spliced isoforms, which differ by the presence or absence of a 12-amino acid peptide at the carboxy terminus of the extracellular ␣-subunit, encoded by exon 11. It has been shown that the exon 11-containing (A) isoform is enriched in embryonic tissues and that it binds Igf2 with high affinity (68). If Insr is indeed a growth-promoting receptor, why are mice lacking Insr considerably less growth retarded than humans lacking Insr? The clue lies in the differing developmental patterns of humans and rodents. Mice are born at an earlier developmental stage than humans. This is reflected, among other features, in differences in body composition. Lipid content at birth represents 16% of total body weight in humans, but only 2% in rodents (240). Adipose tissue development is very sensitive to insulin, as demonstrated by the excessive adiposity of fetuses exposed to hyperinsulinemia of maternal (183, 231) or fetal origin (51), erythroblastosis fetalis (18, 88), and persistent hyperinsulinemic hypoglycemia of infancy (194). Indeed, while it is difficult to apportion the growth effects of insulin due to nutrition versus cell proliferation, the observations that fetuses exposed to hyperinsulinemia primarily increase adipose mass are consistent with the notion that the latter are predominant. Because the acquisition of adipose mass occurs postweaning in rodents, growth retardation in Ins1/Ins2- or Insr-deficient mice is not as severe as in children with leprechaunism. We have confirmed this interpretation using mosaic analysis to introduce partial ablations of Insr function in mice. This was accomplished by conditional mutagenesis, using mice in which floxed Insr alleles have been deleted to various degrees using Cre recombinase driven by the heat shock protein 70 gene promoter. These experiments indicate that, when ⬎80% of somatic cells lose Insr expression, mice develop a phenotype similar to human leprechaunism, with severe postnatal growth retardation and hypoglycemia (122). The growth retardation appears to be due to a ⬎50-fold increase in expression of Igfbp1, a known modulator of Igf bioavailability (44, 71, 72). These data are consistent with two important conclusions: 1) that insulin acting through Insr promotes growth and 2) that it does so by inhibiting hepatic expression of Igfbp1. It should be noted that, postnatally, the growth-promoting actions of Insr are mediated by insulin in rodents, because Igf2 expression virtually ceases after birth (52, 159). In contrast, Igf2 secretion persists throughout life in humans (85), providing an additional element of diversity between the two species (172). 627 INSULIN RESISTANCE IN MICE Physiol Rev • VOL Finally, evidence from mice with mosaic-patterned Insr ablation is also consistent with the view that the difference between hypoglycemia and hyperglycemia may hinge upon muscle glucose utilization. Using the cre/loxP system, we have generated mice with variable degrees of mosaicism for Insr null alleles. In these mice, each tissue is a mixture of Insr-expressing and Insr-knockout cells. Mice in which 80% of cells are devoid of Insr (referred to as ⌬80 mice) develop hypoglycemia. In contrast, mice in which 98% of cells are devoid of Insr (⌬98) develop hyperglycemia. In liver, both groups of mice are equally insulin resistant. Hepatic insulin resistance causes inability to synthesize and store glycogen, which explains the fasting hypoglycemia in ⌬80 mice. In contrast to liver, muscle insulin sensitivity is normal in ⌬80, but reduced in ⌬98 mice. Sensitivity to insulin in muscle would be expected to exacerbate hypoglycemia in ⌬80 mice, because glucose is cleared from the blood and taken up by skeletal muscle. In contrast, resistance to insulin action in muscle of ⌬98 mice results in impaired glucose uptake and hyperglycemia. In summary, the development of hypoglycemia appears to depend on the preservation of muscle insulin sensitivity in the face of hepatic insulin resistance. IV. CONDITIONAL MUTAGENESIS OF INSULIN RECEPTOR The lethal phenotype of Insr knockouts precludes a detailed analysis of insulin receptor function in different tissues in adult mice. Since an impairment of insulin action in one or more insulin target cells is a likely cause of diabetes, several mouse models have been developed to circumvent this limitation (Table 2). These experi- 2. Summary of tissue-specific insulin receptor knockouts TABLE Insr knockout Constitutive Muscle Cardiac muscle Muscle/adipose tissue Adipocyte Brown adipose tissue Liver -Cell Vascular endothelium Central nervous system Mosaicism 84 • APRIL 2004 • Phenotype Reference Nos. Diabetic ketoacidosis Dyslipidemia Reduced heart size and performance Impaired glucose tolerance 4, 101 35 21 Protection against obesity, longevity -Cell failure 28, 29 82 Moderate insulin resistance, transient hyperglycemia Impaired glucose tolerance Protection from hypoxia-induced neovascularization Obesity, subfertility 164 Growth retardation, lipoatrophy, hypoglycemia 122 www.prv.org 140 134 237 34 Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 ing a fast, presumably as a result of limited glycogen reserves in liver (15, 25, 54, 223). In newborn mice, in contrast, feeding is continuous, leading to a steady rise in blood glucose concentrations. A second reason for the absence of hypoglycemia in mice is that -cell compensation for insulin resistance is more robust in humans than in mice. As a result, high insulin levels are maintained only for few days in mice, and for several months in humans. The increase in insulin levels may lead to activation of Igf1r, which in turn stimulates glucose uptake and causes hypoglycemia. We discuss the role of Igf1r in this process in more detail in the section on the muscle-specific Insr knockout. The different compensatory abilities of human and murine -cells result from developmental differences between the two species. Insulin secretion in rodents begins at E15.5, and islets do not become organized until E18.5 (89, 163, 248). Insulin secretion rises about threefold between E18.5 and birth (77, 109, 193). In rodents, the early postnatal period is a time of intense -cell proliferation, and an appropriate -cell mass is generally achieved by 3– 4 wk postnatally (65). In contrast, INS transcripts appear comparatively earlier (8 wk of gestation) in human embryos (30, 185). -Cell clusters can be observed at 12–16 wk (150, 215) and become organized into functioning islets by 25 wk, after which plasma insulin concentrations increase steadily (58). We have shown that pancreatic -cells are morphologically abnormal in Insr knockouts by postnatal day 4, with depleted insulin storage granules and abnormal mitochondria (172). Therefore, mice simply lack sufficient -cell reserve to compensate for insulin resistance. Newborn humans have a greater -cell reserve, which may contribute to hypoglycemia. This explanation is consistent with the clinical observation that hypoglycemia subsides and is gradually replaced by hyperglycemia in children with INSR mutations as insulin secretion deteriorates with age (155, 195). There are also species-specific differences in the role of different tissues in metabolic control, which can partly account for the different presentation of the human and murine phenotypes. Newborn rodents are mostly dependent on liver for fuel metabolism (76), whereas humans rely on muscle and adipose tissue, in addition to the liver. Thus, if the extreme hyperinsulinemia leads to activation of muscle Igf1r and promotes glucose uptake, there is greater potential to cause hypoglycemia in humans than in mice, since muscle glucose disposal is quantitatively more important in humans. This speculation is borne out by studies in which Igf1 treatment of mice lacking Insr results in a rapid decrease of glucose levels, suggesting that Igf1 can indeed stimulate muscle glucose uptake through its receptor. However, this decrease is not sufficient to rescue mice from death (56), presumably because the liver does not possess Igf1 receptors, and thus Igf1 does not rescue hepatic insulin action (114, 181, 199). 628 NANDI, KITAMURA, KAHN, AND ACCILI ments exploit a binary system, in which a mutation of Insr is generated in a restricted pattern by breeding Creproducing and Cre-responding mice. The system has been reviewed elsewhere (136). It bears emphasizing that, although these experiments are described for simplicity as “tissue-specific” knockouts, they should be more properly defined as “Cre promoter-specific.” In other words, the pattern and extent of tissue recombination is dependent on the specificity of the promoter used to drive Cre expression, which is rarely, if ever, limited to a single tissue or cell type and, even within a given cell type, may be limited to a specific developmental stage. In humans, skeletal muscle is the primary site of insulin-dependent glucose disposal (64). Resistance of skeletal muscle to insulin-dependent glucose uptake and phosphorylation is an early step in the development of type 2 diabetes (45). To examine the role of insulin receptors in muscle metabolism, and how the latter affects the development of diabetes, we inactivated Insr in this tissue using MCK-Cre transgenics to excise Insr exon 4, leading to a null allele (muscle insulin receptor knockout, MIRKO). Conditional Insr knockout in skeletal muscle leads to impaired insulin signaling and decreased insulindependent glucose transport, without systemic insulin resistance (35). This is similar to the phenotype of mice carrying a dominant negative Insr transgene in muscle and a heterozygous systemic Insr knockout. These mice fail to develop diabetes, despite a ⬎90% decrease in insulin receptor kinase activity and a sizable decrease in insulin-dependent glucose uptake in muscle (140). These observations, reported by different laboratories using independent experimental approaches, are unexpected. Whereas it is generally accepted that insulin resistance per se, in muscle or elsewhere, is not sufficient to cause overt diabetes, the expectation was that an impairment of insulin signaling in muscle would lead to systemic insulin resistance. Although this was not the case, MIRKO mice develop a metabolic syndrome with increased fat stores and hypertriglyceridemia. Several recent models of targeted gene knockout have helped us to clarify this apparent conundrum. First, it appears that two alternative pathways of glucose uptake compensate for the lack of insulin signaling, including Igf1r (208) and contraction-activated signaling (243). The latter acts through unidentified mechanisms, which may involve AMP-activated protein kinase, and thus independently of the insulin receptor tyrosine kinase (167) (Fig. 2). In further evaluation of the MIRKO mice, hyperinsulinemic euglycemic clamps demonstrate that there is a significant decrease in insulin-stimulated glucose transport and glycogen synthesis in muscle. However, there is Physiol Rev • VOL FIG. 2. Divergent pathways of glucose transporter translocation. There appear to be at least three different pathways regulating GLUT4 translocation and leading to glucose uptake and utilization in muscle. In addition to activation of Insr, contraction is a powerful trigger to GLUT4 translocation through activation of the AMP-activated kinase. In addition, muscle Igf1r signals through Irs proteins and PI3K to stimulate GLUT4 translocation via activation of Akt and other PIP3-dependent kinases, such as protein kinase C isoforms. These pathways explain why an isolated Insr knockout does not suffice to cause insulin resistance to glucose uptake, while a muscle-specific Glut4 knockout causes severe insulin resistance and diabetes. also a concurrent increase in insulin stimulated glucose transport in adipose tissue (116). This suggests that changes in glucose metabolism in adipose tissue may in part compensate for the muscle-specific insulin resistance in MIRKO mice. This phenomenon also explains the finding of more severe insulin resistance with disruption of insulin signaling in both muscle and adipose tissue (140). MIRKO mice do not demonstrate differences in the expression of signaling proteins such as Irs1 or p85␣, suggesting that upregulation of these genes is not important in the compensatory mechanism (35). Likewise, muscle Glut4 levels in MIRKO mice are not altered, indicating alternate regulatory pathways leading to translocation of Glut4 transporters. A potential compensatory pathway is that mediated by Igf1r (Fig. 2). Although changes in Igf1r expression or insulin-stimulated Igf1r phosphorylation are not noted in this case, transgenic mice with dominant negative mutations of Igfr targeted to skeletal muscle do indeed develop diabetes, insulin resistance, and -cell dysfunction. The dominant negative Igf1r transgene inhibits both Igf1 and insulin receptors by forming homo- and heterodimers (“hybrid receptors”) with endogenous receptors and thereby preventing their autophosphorylation (63). The notion that inactivation of Insr in muscle may not suffice to impair glucose metabolism is further supported by results from muscle-specific inactivation of the Glut4 (254). The reduction in insulin- and contraction-stimulated glucose transport seen in these mice is accompanied by early development of insulin resistance and glucose intolerance. Surprisingly, these mice also demonstrate 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 A. Skeletal Muscle INSULIN RESISTANCE IN MICE B. Heart Defects in cardiac metabolism are among the most common comorbidities in type 2 diabetes, but the role of insulin resistance in their pathogenesis, as opposed to hyperglycemia and dyslipidemia, is unclear. The question has been addressed by generating mice in which Insr knockout is restricted to the heart by way of the cardiacspecific ␣-myosin heavy chain promoter (CIRKO). Ablation of insulin signaling in cardiomyocytes resulted in smaller hearts, due to reduced cardiomyocyte size. Interestingly, glucose uptake and glycolysis were increased when measured in perfused hearts, probably due to a compensatory increase in Glut4 expression. In contrast, the heart’s ability to oxidize fatty acids was decreased, and cardiac performance was moderately impaired (21, 211). Tellingly, the CIRKO hearts are also more prone to injury and failure when subjected to pressure overload (96). These findings indicate that insulin resistance may affect cardiac performance independently of changes in lipid and glucose levels. C. Adipose Tissue Adipose tissue accounts for a small percentage of total glucose uptake, 20% of an oral glucose load in humans (78, 160) and 3–5% of glucose uptake during euglycemic hyperinsulinemic clamps in rats (198). Nevertheless, an early component of insulin resistance in type 2 diabetes involves increased lipolysis and decreased glucose transport in the adipocyte. Furthermore, insulin has been implicated as an important player in the maintenance of key adipocyte functions, including adipogenesis, stimulation of glucose uptake as well as lipid synthesis, and inhibition of lipolysis (197). To further identify the Physiol Rev • VOL specific role of insulin signaling in adipocyte function and its contribution to glucose metabolism, mice with Insr knockout limited to white and brown fat tissues (FIRKO) have been generated using a Cre transgene driven by the adipose-specific aP2 promoter (29). FIRKO mice demonstrate significant defects in insulin-mediated glucose uptake and in the ability of insulin to inhibit isoproterenol-stimulated lipolysis. Although basal glucose uptake remains intact, there is evidence of increased basal lipolysis. These findings are associated with decreased fat mass and whole body triglyceride content. This difference is not secondary to a decrease in adipocyte number, but rather corresponds to a polarization of adipocyte size into large and small cells. Leptin levels in these mice are comparable to the wild-type strain, indicating an unexpectedly high level for the apparent fat mass. To assess the effects of hyperphagia on adipocyte development in these mice, gold thioglucose (GTG) treatment was utilized to introduce specific lesions in the ventromedial hypothalamus. Interestingly, despite increased food intake, FIRKO mice do not demonstrate the expected increase in adipose tissue mass. Moreover, intraperitoneal glucose tolerance tests indicate that hyperphagic FIRKO mice fail to develop insulin resistance or abnormal glucose tolerance. In summary, it appears that insulin signaling in adipose tissue is not critical for the maintenance of euglycemia in mice but is required for the development and maintenance of normal triglyceride stores, inhibition of lipolysis, and insulin-stimulated glucose uptake. As seen in muscle, selective knockout of Glut4 in adipose tissue has a more profound effect, indicating a major difference in the whole body response to insulin resistance at different steps of the insulin action cascade (2). A further interesting phenotype noted in the FIRKO mice is a 20% increase in mean life span, with parallel increases in median and maximum life spans. These data support the notion that a decreased fat mass can affect life span independently of caloric restriction (29). These findings are of interest in the context of the association between longevity and mutations in the insulin/IGF signaling pathway in Caenorhabditis elegans (81, 108, 118, 146, 228). D. Brown Adipocyte Brown adipose tissue is thought to play an important role in determining peripheral insulin sensitivity (157), as well as thermal adaptation. Insr has been inactivated selectively in this tissue (BATIRKO) using the uncoupling protein-1 (UCP1) promoter to drive Cre expression. Although brown adipose tissue develops normally in these mice, it hypotrophies gradually with age, with a 50% reduction at 3 mo, and ⬃75% by 6 –12 mo. Interestingly, the 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 impaired insulin-stimulated glucose uptake in adipose tissue and suppression of gluconeogenesis in the liver. Phlorizin treatment leads to a restoration of insulin sensitivity in adipocytes and liver, indicating that these defects are probably secondary to hyperglycemia or glucose toxicity (117). Therefore, although MIRKO mice do not demonstrate significant insulin resistance or diabetes, the phenotypes of mice expressing dominant negative Igf1r and musclespecific knockout of Glut4 confirm the critical role of muscle tissue in glucose metabolism. Various compensatory mechanisms, including increased glucose transport by adipose tissue, suppression of gluconeogenesis in the liver, and activation of Igf1r are able to prevent the development of insulin resistance and diabetes. These studies also indicate that insulin receptor signaling is only one of the pathways leading to Glut4 translocation and glucose uptake in skeletal muscle. 629 630 NANDI, KITAMURA, KAHN, AND ACCILI age-dependent loss of brown adipose tissue is associated with deterioration of -cell function and decrease of -cell mass, giving rise to hyperglycemia (82). This observation suggests that the maintenance of an adequate -cell mass requires brown adipose tissue. It remains to be determined whether this is an endocrine effect of factors produced in brown adipose tissue, or whether it reflects a broader metabolic change. It is also unclear why this phenotype is not observed in FIRKO mice, which carry Insr mutations in both brown and white adipocytes. action (66), suggesting that hepatocyte insulin signaling is required for both direct and indirect control of hepatic glucose production. As LIRKO mice age, there is a concomitant improvement in the metabolic phenotype. This is not secondary to an amelioration of hepatic insulin resistance, but it appears to be due to functional and morphological changes in the liver itself, mediated by the absence of hepatic insulin receptors (164). Thus insulin receptors in hepatocytes are critical in regulating glucose homeostasis, facilitating insulin clearance, and maintaining normal hepatic function. E. Hepatocytes Physiol Rev • VOL F. Vascular Endothelium Vascular endothelium is a target of Insr signaling, and several physiological functions have been ascribed to Insr in this cell type (16). However, these functions are sometimes at odds. For example, insulin has been shown to promote nitric oxide (NO)-mediated relaxation of smooth muscle cells and to protect these cells from apoptosis. However, it has also been shown to act as a potent stimulator of vascular epidermal growth factor (VEGF) and endothelin expression, which would be expected to cause vasoconstriction and potentially lead to hypertension. Moreover, it has been suggested that Insr in vascular endothelium may contribute to delivery of insulin to target cells through a transcytosis process (119, 216). Finally, there is evidence that insulin is a vasodilator in vivo (17, 31) and that some of its effects on glucose uptake may be secondary to increased tissue blood flow (247). Mice lacking Insr in vascular endothelium display slight reductions of arterial blood pressure under both low- and high-salt diets and are mildly insulin resistant. Expression of endothelial NO synthase (eNOS) and endothelin-1 are reduced by ⬃30 – 60% in endothelial cells, without changes in Vegf expression (237). The failure of these mice to develop hypertension, either basally or in response to a high-salt diet, refutes the notion that the association between insulin resistance and hypertension can be explained by insulin’s action on the vascular endothelium. Similarly, the lack of significant insulin resistance indicates that insulin transport across the endothelial barrier is not limiting for peripheral insulin action. It remains to be seen whether the changes in vasoactive peptide expression predispose to altered vascular reactivity under conditions of increased genetic susceptibility to vascular injury. Interestingly, when these mice are subjected to chronic hypoxia, they display a decrease in retinal neovascularization, the primary cause of diabetic retinopathy and blindness (128). These data, along with similar, albeit less pronounced data in mice lacking Igf1r in vascular endothelium, suggest that increased activation of insulin/ 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 The liver plays a central role in the control of glucose homeostasis and is subject to complex regulation by substrates, insulin, and other hormones. The liver appears to be even more important in insulin sensitivity in rodents, as indicated by the fact that, as long as hepatic insulin action is preserved, mice are protected from diabetes (140). The physiological basis of this observation remains unclear but can potentially relate to species-specific differences in glycogen storage. In fact, rodents store a larger proportion of total body glycogen in liver, compared with humans (95). Insulin resistance in the liver, in particular the loss of its ability to suppress hepatic glucose output, is closely correlated with fasting hyperglycemia in type 2 diabetes. Insulin affects hepatic glucose suppression initially by inhibiting glycolysis. With prolonged fasting, however, insulin reverts to the alternate pathway of inhibiting gluconeogenesis. There is considerable debate as to whether this latter phenomenon is secondary to a direct effect of insulin on the liver or rather an indirect effect mediated by insulin’s action on muscle and fat to decrease the supply of gluconeogenic precursors (40). In addition to their effect on suppression of glucose production, the hepatic insulin receptors are believed to play an important role in the degradation and clearance of insulin by the liver. Thus hepatic insulin resistance may in part account for the hyperinsulinemic state found in type 2 diabetes. With the use of the Cre-loxP system, with an albumin promoter to mediate liver specific Cre expression (187), it has been possible to investigate the direct effects of loss of insulin receptor function in the liver. By 2 mo age, liver-specific Insr knockout (LIRKO) mice exhibit dramatic elevations in blood glucose levels. Intraperitoneal glucose tolerance tests confirm severe glucose intolerance. In addition, they develop marked hyperinsulinemia due to a combination of increased -cell mass and decreased insulin clearance, as well as failure of insulin to suppress hepatic gluconeogenesis (164). Euglycemic, hyperinsulinemic clamp studies reveal that this loss of regulation of gluconeogenesis is due to the direct effects of insulin on the liver, rather than the indirect pathway of INSULIN RESISTANCE IN MICE Igf signaling pathways may be pathogenetically related to proliferative retinopathy and provide an explanation for the paradoxical observation that, in some patients, intensive insulin therapy accelerates the onset of retinopathy (49, 200). It should be said, however, that the Diabetes Control and Complications Trial did not confirm these findings (226a, 226b). G. Neurons Physiol Rev • VOL similar to the NIRKO mice (176). Furthermore, insulin clamp studies in these rats have shown ineffective suppression of hepatic gluconeogenesis in the setting of hyperinsulinemia (177). Interestingly, unlike the findings in the NIRKO mice, short-term inhibition of Insr in the arcuate nucleus increases NPY and Agouti-related peptide (AGRP) levels, but does not alter POMC levels. Further analysis of the mechanisms by which hypothalamic Insr may affect insulin-mediated suppression of hepatic gluconeogenesis suggests that ATP-sensitive potassium channels rather than central melanocortin receptors are important in this process. Although the role of brain Insr in coordination of fuel metabolism, nutrient sensing, and fertility could be considered surprising, it does appear to serve a teleological function by connecting these various functions, thus limiting reproduction in times of food deprivation. These findings corroborate earlier work in C. elegans demonstrating the importance of insulin/Igf signaling in the nervous system on reproduction and life span (10). H. Pancreatic -Cell Although peripheral insulin resistance is one of the hallmarks of type 2 diabetes, development of diabetes requires the onset of -cell dysfunction. Multiple defects in insulin secretion and -cell mass have been noted in patients with type 2 diabetes and also during the insulinresistant prediabetic stage. There appears to be a genetically determined tendency to -cell dysfunction. However, the particular mechanisms leading to these defects have not yet been completely elucidated (186). Classically, insulin secretion has been thought to be regulated by the products of glucose metabolism in the -cell (161). To address the role of insulin signaling in these processes, Insr has been inactivated in mature -cells using a minimal Insulin2 promoter to drive credependent recombination (IRKO). These mice demonstrate a selective impairment in the first phase of glucosestimulated insulin secretion, a phenotype reminiscent of that seen in type 2 diabetes patients (Fig. 3). This defect ultimately leads to age-dependent glucose intolerance and, in some mice, to overt diabetes. These data suggest that the insulin-resistant state in type 2 diabetics may, in part, also be responsible for the defect in insulin secretion that is seen in this disease (134). It is unclear how Insr controls insulin secretion. The pancreatic portal system is designed to provide for insulin control of glucagon secretion, but more work is required to determine the mechanism of Insr regulation of insulin secretion. Nevertheless, the idea that Insr signaling regulates insulin production and exocytosis is teleologically attractive, in that it would provide a unifying mechanism for insulin resistance and impaired -cell function. 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 Insulin and Igf1 receptors are expressed at high levels in many areas of the brain and in different cell types, including glial and neuronal cells (87). Because neurons metabolize glucose in an insulin-independent manner, the role of Insr in the brain has remained somewhat arcane (205). The question as to the potential function of neuronal Insr has been addressed by generating neuron-specific Insr knockout mice (NIRKO) using nestin/Cre-mediated ablation (34). Loss of Insr in nestin-positive neurons does lead to mild insulin resistance and hypertriglyceridemia. Interestingly, there is also a dramatic increase in food intake in female mice, while increases in adipose tissue depots occur in both male and female mice. This suggests that, in addition to glucose metabolism, Insr is important in brain nutrient sensing and regulation of energy expenditure. A further, unexpected result in NIRKO mice is impaired male and female fertility. Initial assessment indicates hypogonadotrophic hypogonadism in relation to defective spermatogenesis and follicular maturation. Further studies have indicated normal pituitary luteinizing hormone (LH) content and response to exogenous gonadotropin, suggesting a hypothalamic defect leading ultimately to altered gonadotropin expression. Evaluation of hypothalamic hormones that affect fertility and food intake has revealed increased proopiomelanocortin (POMC) without significant changes in neuropeptide Y (NPY) levels (J. Bruning, personal communication). It is notable that Irs2 knockout mice, in addition to developing diabetes, also demonstrate abnormalities in food intake, increased obesity despite elevated leptin levels and infertility, particularly in the females (38). The reproductive abnormalities are associated not only with fewer ovarian follicles but also decreased pituitary size and gonadotroph numbers. Although these mice represent a generalized lack of Irs2 protein, the phenotypic similarities with NIRKO mice suggest that Irs2 is important in modulating insulin’s role in regulation of hypothalamic functions in energy expenditure, food intake, and fertility. Studies to define the specific role of hypothalamic Insr signaling have utilized short-term intracerebroventricular infusions of antisense oligonucleotides directed against the Insr in rats. The subsequent downregulation of Insr expression in the medial portion of the arcuate nucleus leads to hyperphagia and increased fat mass, 631 632 NANDI, KITAMURA, KAHN, AND ACCILI Similar to Insr, Igf1r ablation in -cells affects insulin secretion and results in fasting hyperinsulinemia with impaired glucose tolerance (Fig. 3). The likeliest cause of these combined abnormalities is that basal insulin secretion is increased, but glucose-stimulated insulin secretion is impaired. Indeed, electron microscopic analysis of Igf1r-deficient -cells revealed a depletion of insulin storage granules, and an increase in the amount of rough endoplasmic reticulum and Golgi stacks, consistent with a state of constitutively active secretion. These finding are consistent with the known effect of Igf1 to inhibit insulin secretion from -cells (252) and perfused rat pancreas (145). Notably, despite the fact that it is expressed at higher levels in -cells than either insulin or Igf1 receptors (90), the Irr does not appear to be involved in -cell function. In fact, metabolic analyses and insulin release studies from purified islets of Irr knockouts have failed to demonstrate a role for this receptor in -cell function (120). I. What Is the Role of Insulin Signaling in Pancreatic -Cells? As noted above, -cell dysfunction is a sine qua non for development of the diabetes phenotype and may also play a role in the insulin-resistant state. In states of metabolic dysregulation, defects are seen in both insulin secretion and compensatory changes in -cell mass. There is substantial evidence for a role of receptor tyrosine kinases in insulin synthesis and release, as well as -cell proliferation and survival (Fig. 3). Inactivation of Insr (134), Igf1r (135, 245), and Irs1 (137) leads to defective insulin secretion in response to glucose and amino acids. On the other hand, inactivation of Irs2 leads to reduced -cell mass (242), presumably for lack of neogenesis or increases in apoptosis. Overexpression of Akt in -cells increases neogenesis and results in increased Physiol Rev • VOL -cell mass and size, without affecting insulin secretion (24, 230), while ablation of its substrate p70s6k1 results in decreased cell size and hypoinsulinemia. In contrast, mutations of the eukaryotic translation initiation factor 2␣ (eIF2␣) (204) and its kinase Perk (86) impair the metabolic stimulus/secretion coupling, presumably by affecting Insulin mRNA translation. While it is clear that tyrosine kinase signaling is important for -cell proliferation and survival, evidence that Insr and/or Igf1r are the receptors that promote -cell growth is, at this point, inconclusive. The main supportive data derive from the Irs2 knockout and from observations that haploinsufficiency for either Igf1r (241) or Insr (123) in the Irs2 null background accelerates -cell demise and results in rapid-onset diabetes. On the other hand, it is disappointing that neither the Insr nor the Igf1r -cell specific knockout results in alterations of -cell mass or proliferation. Derivation of mice bearing a double mutation of both genes should address whether this is a result of compensation by the cognate receptor. A possible interpretation of these data is that Irs2 is activated in -cells in response to other cues, such as -cell specific growth factors (67, 73, 235, 236). This explanation would be consistent with the observation that neither Insr nor Igf1r appears to be necessary for embryonic growth of the endocrine pancreas, while they have a major effect on exocrine pancreas development (112). However, as stated above, embryonic development of the endocrine pancreas is rather limited in mice, since -cell proliferation occurs mostly postnatally (65, 245). Thus it is possible that Insr and Igf1r affect postnatal, but not embryonic, -cell proliferation/survival. An alternate explanation, which we tend to favor (3, 123), is that Insr and/or Igf1r are important for -cell neogenesis through proliferation and terminal differentiation of -cell precursors. If that were the case, ablation of the two receptors induced by the -cell-specific insulin 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 FIG. 3. Mutations of Insr and Igf1r signaling in pancreatic -cells. Insr and Igf1r knockouts in -cells have been obtained using the insulin promoter to drive cre expression. In both instances, insulin secretion is impaired, albeit the mechanisms appear to differ. The effect of Irs1 knockout on -cells is similar to that of Igf1r, suggesting that Irs1 lies downstream of Igf1r. Alterations of insulin secretion result also from mutations of PI3K. Although ablation of Irs2 has a profound effect on -cell proliferation, neither receptor knockout affects this aspect of -cell physiology. Thus it is possible that Irs2 is activated by additional receptors. A prime candidate was Irr, but studies of Irr knockouts rule out an effect on -cell proliferation and glucose-induced insulin secretion. INSULIN RESISTANCE IN MICE V. Igf1r KNOCKOUT Lack of Igf1r impairs fetal growth (mice weigh 45% of normal) but is compatible with fetal development (59). Mice are born with multiple abnormalities, including hypoplastic muscles, delayed bone development, and thin epidermis and die from respiratory failure immediately after birth (153). Compared with the extreme metabolic phenotype due to lack of insulin receptors, it appears that Insr and Igf1r play very different roles. However, there exists some functional overlap. This is more evident in the ability of Insr to substitute for the growth-promoting actions of Igf1r than in the latter’s ability to substitute for the metabolic actions of Insr. For example, ablation of both Igf1r and Igf2r results in normal mice (158), presumably due to the ability of insulin receptors to stimulate growth and substitute for the actions of Igf1r. It is important to emphasize that this is possible by virtue of an increase in Igf2 levels caused by the ablation of Igf2r (158). On the other hand, administration of Igf1 to Insr-deficient mice does not result in prolonged survival, although it does decrease glucose levels by increasing muscle glucose uptake (56). Withers et al. (241) have reported an increase in glucose levels and -cell hypoplasia in Igf1rdeficient mice. However, it is unlikely that the magnitude of the hyperglycemia would suffice to account for the early postnatal death, considering that even insulindeficient mice survive a few days (57). With respect to the issue of diverging signaling properties between Insr and Igf1r, in vitro studies with hepatocytes derived from Insr-deficient mice have begun to Physiol Rev • VOL provide some mechanistic insight into this phenomenon. These experiments suggest that there are intrinsic signaling differences between Insr and Igf1r that make Insr more suited to metabolic signaling than Igf1r (113, 170, 181, 199). VI. INSULIN RESISTANCE CAUSED BY MUTATIONS OF GENES ENCODING PROTEINS IN THE INSULIN SIGNALING PATHWAY A. Irs Signaling Irs proteins mediate insulin, IGF, and cytokine actions (239) (Fig. 1). The Irs family is composed of four closely related members (Irs1 to -4) (142, 143, 218, 219) and a more distantly related homolog, Gab1 (92). It is conceivable that the presence of a unique complement of phosphotyrosines in each molecule would allow for differential signaling. In addition, there are distinctive patterns of tissue expression, such that each Irs protein may play a different role in different tissues (110, 239). The results of gene inactivation experiments are consistent with the view that Irs proteins have different specificities and functions (Fig. 4). B. Irs1 Knockout The main consequences of Irs1 inactivation in mice are intrauterine and postnatal growth retardation, associated with mild insulin resistance without diabetes (13, 221). These findings indicate that Irs1 mediates the growth-promoting actions of Igf1r, but plays a secondary role in metabolic signaling. Nonetheless, lack of Irs1 has also been shown to impair insulin secretion from -cells (137), suggesting that insulin/IGF1 signaling through Irs1 is required for proper -cell function. Moreover, combined heterozygosity for Insr and Irs1 null alleles causes a severe impairment of insulin action associated with a steep rise in the incidence of diabetes in the resulting progeny (36, 110), suggesting that Irs1 has an important role on insulin action. These experiments are reviewed below. C. Irs2 Knockout Mice lacking Irs2 develop diabetes due to a combination of insulin deficiency and impaired insulin action. The disease is lethal in some genetic backgrounds (242) and milder in others (132). The metabolic syndrome is due to combined insulin resistance in peripheral tissues (110, 190) and impaired growth or increased apoptosis of pancreatic -cells (123, 138). The findings in the Irs2- 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 promoter would not affect neogenesis, since this promoter should be inactive in precursor cells. As our understanding of the elusive -cell precursor increases, it should be possible to address the function of the two receptors in the -cell differentiation process. The role of PI3K also presents a complex picture (Fig. 3). Pharmacological inhibition of PI3K signaling by wortmannin is associated with increased insulin release from purified islets (251). Indeed, Eto et al. (61) have shown that islets from mice lacking the PI3Kr subunit have increased insulin secretion, due to elevation in cytosolic calcium levels. This is in contrast to data in Insr, Igf1r, and Irs1 knockouts, in which insulin secretion appears to be blunted and calcium signaling unaffected (14, 134, 135, 137, 147, 148, 245). This discrepancy may reflect different experimental conditions and different measurements performed in each study. However, as pointed out by Eto et al. (61), it is also possible that different steps of the exocytotic process may be affected in opposite ways by defects in PI3K signaling. 633 634 NANDI, KITAMURA, KAHN, AND ACCILI deficient mouse recapitulate the natural history of type 2 diabetes and have led to the suggestion that IRS2 mutations may predispose to diabetes in humans, a conclusion that is not borne out by the genetic analyses carried out thus far (8, 20, 23). These data are consistent with an important role of Irs2 in fuel homeostasis, but also underline the conclusion that multiple substrates are required to mediate insulin action, since the phenotype due to lack of insulin receptors is substantially more severe than that due to lack of Irs2. D. Irs3 Knockout Irs3 is the most abundant Irs protein in adipocytes (213, 244), but is also found in other tissues (143, 206). Lack of Irs3 has no apparent effect on mouse development and metabolism, or on insulin-dependent glucose uptake in isolated adipose cells (154). However, this may be due to compensation by Irs1 in adipose cells, as described below. It should be noted that humans lack IRS3 (27). VII. DOUBLE Irs GENE KNOCKOUTS A. Irs1 and Irs2 Mice lacking both Irs1 and Irs2 die before implantation on the C57BL ⫻ 129SV background, resulting in one of the most dramatic embryonic lethal phenotypes observed in mice with targeted gene mutations (241). It is important to note that this phenotype is substantially more severe than the phenotype due to combined lack of Insr and Igf1r, suggesting that Irs proteins play additional roles to mediate the actions of other receptors, as predicted by studies of cytokine receptor signaling (239). On the other hand, the metabolic phenotype of Irs1⫺/⫺ Irs2⫹/⫺ mice, bearing the minimum number of Irs1 and Irs2 alleles compatible with live birth, is significantly milder than the Insr knockout phenotype, suggesting that the metabolic actions of insulin may require more than Irs1 and Irs2 signaling (241). However, it should also be noted that double-mutant embryos can be recovered from crosses of single mutants in a different background (DBA ⫻ 129SV) (165), suggesting that the actions of Irs1 and Irs2 are dependent on modifier genes. E. Irs4 Knockout B. Irs1 and Irs3 Ablation of Irs4 results in a mild phenotype with reduced growth, impaired glucose tolerance, and reproductive abnormalities (62). This phenotype is reminiscent of the Irs1 knockout phenotype, albeit considerably milder. Physiol Rev • VOL An additive effect is seen when Irs1 and Irs3 knockouts are intercrossed. Combined deficiency of these two proteins causes lipoatrophy with insulin resistance. Unlike other lipoatrophic models, Irs1/Irs3 knockouts fail to 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 FIG. 4. Tissue-specific functions of Irs proteins. Different Irs proteins appear to have specific roles in different tissues. These conclusions are supported by knockout studies. Irs1 appears to be the main mediator of insulin signaling in skeletal muscle, adipose tissue, and -cell secretory function. Irs2 is important for liver metabolism and -cell proliferation/protection from apoptosis. Irs3 plays an ancillary role in the fat cell, as demonstrated by the lipoatrophy of double-mutant mice lacking both Irs1 and Irs3. The function of Irs4 is elusive. Mice lacking Irs4 have a mild phenotype of growth retardation and hyperinsulinemia, but the phenotype of double mutants Irs1/Irs4 is the same as in Irs1 knockouts. INSULIN RESISTANCE IN MICE develop intrahepatic and intramuscular deposits of triglycerides. As predicted from other models of lipoatrophy, leptin administration reverses the hyperglycemia and hyperinsulinemia (141). C. Irs1 and Irs4 D. Akt The primary function of PI3K in insulin and growth factor signaling appears to be the transduction of tyrosine phosphorylation into a signal leading to activation of serine/threonine kinases. This is accomplished via generation of tris-phosphorylated inositol (PIP3), which in turn acts as a ligand for kinases containing a PH domain. The PIP3-dependent kinase Pdk1 activates a family of serine/ threonine kinases grouped under the acronym of AGC kinases. They include p70s6k, Akt, and Sgk isoforms (149, 234). The role of Pdk1 in insulin action awaits further elucidation. A complete knockout is embryonic lethal, while hypomorphic alleles are associated with decreased cell size (144). Among the Pdk1 targets, Akt stands out because of its brisk insulin-dependent activation (127) and ability to mimic many of insulin’s actions when overexpressed (50). A delineation of its precise role in physiological processes has been hampered by the fact that complete inhibition of its activity appears to be incompatible with cell survival, and by the presence of three highly homologous isoforms in most cell types. However, mice lacking Akt2 have recently been generated. Two phenotypes have been reported: in one instance, mice show evidence of impaired insulin signaling in muscle and adipocytes, which is however insufficient to cause overt diabetes (42). In another experiment, the phenotype is more pronounced, with growth retardation, reduced fat mass, and diabetes (74). The latter phenotype is quite similar to that of Irs-deficient mice. Whether these phenotypic differences are due to compensation by related isoforms remains unclear, but the data are consistent with an important role of Akt in insulin action. When both Akt1 and Akt2 are inactivated, the phenotype resembles closely that of Igf1r-deficient mice (184). Because of the early postnatal lethality, it has not been possible to determine whether metabolic control is also impaired in the double Akt-deficient mice. As detailed elsewhere in this review, Akt appears to be central to -cell function as well (24, 230). Physiol Rev • VOL E. Glut4 Insulin-dependent glucose uptake requires Glut4 translocation from an intracellular compartment to the plasma membrane (175). Thus interest in Glut4 defects as a cause of insulin resistance has been keen. Mice with a complete Glut4 knockout are growth retarded and show cardiac hypertrophy and underdeveloped adipose tissue. They develop moderate insulin resistance, which in male animals is associated with hyperglycemia in the fed state. Female mice do not develop hyperglycemia (106). Somewhat surprisingly, heterozygous males develop insulinresistant diabetes, without obesity (217). It is not clear why heterozygotes are more severely affected than homozygotes, but it could be due to the fact that additional glucose transporters, such as GlutX/Glut8 (100), can be induced in mice lacking Glut4, but not in heterozygous knockouts, thus leading to metabolic compensation only in homozygous knockouts. F. Heart-Specific Glut4 Ablation The presence of cardiac abnormalities in Glut4-deficient mice is of great interest, in view of the increased incidence of cardiac disease in insulin-resistant patients (107). To determine whether the cardiac hypertrophy seen in Glut4-deficient mice is a primary result of Glut4 deficiency in the heart or a consequence of metabolic abnormalities, the cre-loxP system has been used to generate mice lacking Glut4 in the heart. These mice show increased basal levels of glucose uptake but fail to respond to insulin. The metabolic abnormality results in compensated cardiac hypertrophy associated with increased cardiomyocyte size and preserved contractile function (1). In addition, recovery from ischemic damage is impaired in the Glut4-deficient heart (227). The data indicate that Glut4 is important for cardiac function. G. Muscle-Specific Glut4 Ablation The phenotype of mice lacking Glut4 indicates that Glut4 is required for insulin-dependent glucose uptake, but not for maintenance of metabolic homeostasis. This surprising conclusion is consistent with the observation that mice with a targeted Insr inactivation in skeletal muscle do not develop obvious metabolic changes (35, 140). To better evaluate the contribution of Glut4 to muscle metabolism, mice lacking Glut4 in skeletal muscle have been generated. Unlike total Glut4 knockouts, muscle-specific Glut4 knockouts are moderately insulin resistant and glucose intolerant, consistent with an important role for Glut4 in glucose metabolism (254). Further analysis of these mice indicates a significant increase in hepatic glycogen storage, an indicator of hepatic glucose 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 Mice with combined ablation of Irs1 and Irs4 show the same phenotype as Irs1 knockouts, with growth retardation and mild insulin resistance, suggesting that Irs4 is not a primary mediator of insulin and Igf action (141). The lack of additive effects of the two phenotypes indicates that the functions of Irs1 and Irs4 are overlapping. 635 636 NANDI, KITAMURA, KAHN, AND ACCILI these mice. This model supports the importance of Glut4mediated glucose transport in adipose tissue and the indirect effects of insulin action in adipose cells on insulin action in other tissues. I. Genes in the Glut4 Translocation Pathway: Syntaxin4 The molecular effectors of Glut4 translocation from the intracellular pool to the plasma membrane are incompletely characterized. Syntaxin4 has been shown to play a role in Glut4-containing vesicle fusion. While homozygous knockouts are embryonic lethal, heterozygous knockouts show no developmental abnormalities but develop impaired glucose tolerance and a 50% decrease in Glut4 translocation in response to insulin in skeletal muscle, but not in adipose tissue (246). J. Ceacam1 and Insulin Clearance H. Fat-Specific Glut4 Ablation With the use of a similar experimental approach, Glut4 has been selectively ablated in mature adipocytes using the Ap2 promoter to drive cre expression. Mice lacking adipocyte Glut4 fail to increase glucose uptake in response to insulin and develop hyperinsulinemia with hepatic insulin resistance. Because adipocyte-mediated glucose uptake accounts for only ⬃10% of whole body glucose disposal, the phenotype indicates that a change in insulin sensitivity in adipocytes can disproportionately affect metabolic control (2). As observed in mice with muscle-specific Glut4 ablation, the metabolic consequences display individual variations, and only some mice develop diabetes. Unlike the systemic Glut4 knockout, adipose-selective ablation of this transporter does not lead to growth retardation or reduced adipose tissue mass and adipocyte size. While insulin-stimulated glucose transport in adipocytes is severely blunted, glucose transport in muscle appears to be normal in ex vivo experiments in isolated muscle strips, but is impaired in vivo during hyperinsulinemic-euglycemic clamp studies. Because Glut4 levels in skeletal muscle are normal in these mice, it is likely that an indirect mechanism is responsible for this effect. However, there are no changes noted in three potential mediators of these secondary changes: tumor necrosis factor-␣ (TNF-␣), leptin, or free fatty acids (FFA). Of note, insulin-induced suppression of hepatic gluconeogenesis is also impaired in the fat-specific Glut4 knockouts. Therefore, abnormal glucose transport in the adipocyte can lead to insulin resistance and inadequate glucose disposal in distant tissues through chronic hyperinsulinemia or an unidentified secondary agent. However, despite decreased insulin action at the level of the adipocyte, muscle, and liver, overt diabetes does not develop in Physiol Rev • VOL Although hyperinsulinemia is generally thought to be a compensatory response to insulin resistance, it can potentially arise as a primary cause of insulin resistance, by triggering a secondary downregulation of the insulin signaling pathway. For example, overexpression of Igf2 in pancreatic -cells of transgenic mice leads to increased -cell proliferation, hyperinsulinemia, and secondary diabetes (55). The hepatic membrane protein Ceacam has been shown to participate in the process of receptormediated insulin internalization and degradation. Ceacam activation is dependent on the phosphorylation of residues in its intracellular domain (168, 169). To test the hypothesis that defects in Ceacam-dependent insulin internalization result in hyperinsulinemia, transgenic mice expressing a dominant negative Ceacam, in which the key phosphorylation site has been mutated, have been generated. These mice do indeed develop hyperinsulinemia and a metabolic syndrome of increased visceral adiposity and increased triglycerides and FFAs. Thus these findings provide proof of principle for the view that alterations in insulin clearance affect peripheral insulin sensitivity (189). VIII. MIXING AND MATCHING: MODELING THE COMPLEX GENETICS OF TYPE 2 DIABETES THROUGH EXPERIMENTAL MOUSE CROSSES A. Insr Haploinsufficiency and Diabetes Most patients with type 2 diabetes do not have insulin receptor mutations but have acquired a secondary impairment of insulin receptor function (179). In these patients, 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 uptake. The compensatory increase in hepatic glycogen levels may prevent higher incidence of frank diabetes in these mice. Glucose uptake in adipose tissue, however, does not show a similar compensatory increase. Hyperinsulinemic-euglycemic clamps demonstrate that musclespecific Glut4 knockout mice have decreased whole body and insulin-stimulated muscle glucose uptake. In a subset of mice that develops overt diabetes, these studies have revealed also insulin resistance in liver and decreased glucose uptake in adipose tissue. However, the latter defects appear to be secondary to glucose toxicity, since they are reversed by treatment with phlorizin (117). These studies indicate that Glut4 is required for muscle glucose transport. However, since only some of the muscle Glut4 knockout mice develop diabetes, it appears that there are compensatory mechanisms that prevent the onset of hyperglycemia even when muscle glucose utilization is reduced. INSULIN RESISTANCE IN MICE Physiol Rev • VOL NIDDM1 mutation (CALPAIN10), when they also possess certain alleles on chromosome 15 (46), and when the background genes are also permissive. While combined mutations of Insr and Irs1 have provided insight into the polygenic nature of type 2 diabetes, comparisons of double mutant mice with Insr/Irs1 or Insr/Irs2 null alleles have shed light onto the issue of genetic heterogeneity. Genetic heterogeneity means that mutations in different genes can result in a similar phenotype. Indeed, both Insr/Irs1 and Insr/Irs2 double mutant mice develop diabetes at similar rates. However, the Insr/Irs1 mice do so because they are primarily insulin resistant in skeletal muscle, whereas the Insr/Irs2 mice do so because they are primarily insulin resistant in liver (110). These data indicate that different insulin receptor substrates play tissue-specific roles, with Irs1 being the primary mediator of insulin action in muscle and Irs2 in liver (190). IX. GENE KNOCKOUTS ASSOCIATED WITH INCREASED INSULIN SENSITIVITY In addition to mutations affecting insulin action, mutations in genes required to terminate or modulate insulin signaling have proven very informative in examining the pathophysiology of insulin resistance (Fig. 5). FIG. 5. Negative regulators of Insr signaling. Several gene knockouts have insulin-sensitizing effects. Mice lacking the tyrosine phosphatase Ptp1b are refractory to diet-induced insulin resistance, possibly resulting from reduced tyrosine dephosphorylation of Insr and its main substrates. Ablation of the regulatory p85 subunit of PI 3-kinase restores insulin sensitivity in Insr and Irs1 knockout mice, due to increased activation of PI3K-dependent responses. Mutations of the inositol-phosphatase Ship-2 cause neonatal hypoglycemia, and mice heterozygous for the Ship2 null allele reveal increased glucose tolerance. Pharmacological or genetic inhibition of IKK -kinase protects mice against dietinduced insulin resistance, as do mutations ablating JNK1 function. Haploinsufficiency for the forkhead transcription factor Foxo1, which is normally inhibited by Akt-dependent phosphorylation, results in decreased expression of genes regulating gluconeogenesis. 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 normalization of insulin resistance through various regimens (diet, exercise, and medical therapy) leads to a significant recovery of insulin receptor function (69). To better understand the role of Insr mutations in the genetic predisposition to diabetes, we have studied the phenotype of Insr heterozygous knockouts. As predicted from the description of the tissue-specific knockouts, these phenotypes are rather variable, even within the same experimental cross in the same laboratory. For example, Insr⫹/⫺ mice develop diabetes with a frequency varying between 5 and 10% (36, 110). Back-crosses of the Insr mutation onto different genetic backgrounds indicate that the variability of the metabolic phenotypes due to the Insr mutation is due in part to environmental factors and in part to genetic modifiers, which have been preliminarily mapped (110). The role of genetic background in determining phenotypic differences should be emphasized: with the exception of the insulin receptor itself, virtually all other gene knockouts in the insulin signaling cascade have yielded significantly different phenotypes on different genetic backgrounds. Thus growth retardation in Irs1 knockouts (13, 221) and diabetes in Irs2 (132, 224, 242) and Akt2 knockouts (42, 74) vary in severity depending on the mouse strain in which the experiments were performed. We have also used the Insr heterozygous mutants to mimic genetic interactions leading to type 2 diabetes. A first step in this direction was the development of a polygenic model of insulin-resistant diabetes by crossing mice with heterozygous null mutations of Insr and Irs1. Whereas mice heterozygous for Irs1 deficiency are normal, mice heterozygous for both Insr and Irs1 null alleles develop severe hyperinsulinemia, pancreatic -cell hyperplasia and, by 4 – 6 mo of age, 50% of these mice become frankly hyperglycemic. This process closely resembles the pathogenesis of human diabetes, in which insulin resistance is a chronic process and leads gradually to -cell failure (36, 110). Thus even a major predisposing allele, such as the null Insr mutation, has a modest effect by itself, but plays a major role in the context of a predisposing background. Indeed, when the double heterozygous knockout mice are bred onto different genetic backgrounds, the prevalence of diabetes can vary from ⬍2 to 85% (9, 133). Interestingly, the relative risk of diabetes in double heterozygous offspring (Ir/Irs1⫹/⫺) of single heterozygous Insr or Irs1 parents increases fourfold, similar to the excess risk of diabetes in first degree relatives of humans with diabetes (75). The findings in the Insr/ Irs1⫹/⫺ mouse are consistent with an oligogenic mode of inheritance of type 2 diabetes, in which two subclinical defects of gene function, coupled with effects of background genes, can account for virtually the entire genetic susceptibility to the disease. Gene-gene interactions are also likely to play a role in humans, as suggested by the increased susceptibility to diabetes in carriers of the 637 638 NANDI, KITAMURA, KAHN, AND ACCILI A. Protein Tyrosine Phosphatase B. PI3K Regulatory Subunits It is generally agreed that insulin signaling requires the lipid kinase activity of the enzyme PI3K (175). Nevertheless, it remains unclear whether PI3K is both necessary and sufficient for insulin action (98). The lipid kinase activity is dependent on the enzyme’s p110 catalytic subunit, while the regulatory p85 subunit (PI3Kr) binds Irs in an insulin-dependent manner. The gene Pik3r1 encodes three proteins (p85␣, p55␣, and p50␣) that serve as regulatory subunits of class 1A PI3Ks. Mice lacking the p85 isoform of this subunit show increased insulin sensitivity and hypoglycemia due to increased glucose transport in skeletal muscle and adipocytes (226). This unexpected phenotype is associated with a compensatory increase in insulin-dependent binding of Irs proteins to the alternatively spliced products of PI3Kr (especially p50␣), which was originally proposed to be the cause of increased insulin sensitivity. However, mice lacking all p85 splice isoforms are also hypoglycemic and insulin sensitive (70), so that this explanation is no longer tenable. Unlike the p85-deficient mice, the pan-PI3K1r knockout mice die shortly after birth with multiple abnormalities, consistent with the pleiotropic role of PI3K (70). These experiments provide evidence for a role of PI3K in insulin action but do not address the mechanism by which p85 regulates PI3K Physiol Rev • VOL C. Ship2 The SH2 domain-containing inositol 5-phosphatase Ship2 is able to dephosphorylate phosphoinositol, resulting in abrogation of insulin signaling. As can be anticipated, decreased expression of this protein allows significant enhancement of insulin action. In particular, Ship2 homozygous null mice develop severe and fatal hypoglycemia early in the neonatal stage (43). The low insulin level in these mice indicates that this effect is secondary to increased insulin sensitivity, rather than increased insulin production. This hypothesis is supported by the finding of decreased levels of gluconeogenic enzymes in the liver. Mice heterozygous for the Ship2 null allele live to adulthood but reveal increased glucose disposal during a glucose tolerance test as well as increased Glut4 translocation and glycogen storage in muscle. These data demonstrate both the involvement of phosphoinositides in insulin signaling and the specific role of this class of phosphatases in its negative control. D. c-Jun Amino-Terminal Kinase Serine phosphorylation of Irs and insulin receptors has been shown to dampen insulin signaling, potentially contributing to the onset of the metabolic syndrome (53, 105, 182, 201). Identification of the serine kinases that mediate this event has proven to be an elusive target. In recent years, evidence from knockout mice has begun to shed light on this controversial issue. For example, in vitro evidence from cultured cells has shown that the c-Jun amino-terminal kinases (Jnk) can impair insulin action in response to activation by cytokines and FFAs (5), two agents that are known to cause insulin resistance in vivo. Moreover, Jnk1 activity has been shown to be elevated in obesity. Mice lacking Jnk1 appear to be protected against obesity and insulin resistance of both genetic (obese mutation) and environmental (diet) origin (91). Interestingly, Irs1 phosphorylation on Ser307 is associated with decreased interaction with the insulin recep- 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 Several tyrosine phosphatases have been implicated in the regulation of insulin signaling. However, the identification of Insr- or Irs-specific phosphatases has been stymied by the extreme genetic heterogeneity of this gene family. Disruption of the protein tyrosine phosphatase (Ptp1b) gene in mice leads to improved glucose tolerance, decreased glucose levels, and decreased insulin levels, consistent with a state of heightened insulin sensitivity. Increased Insr phosphorylation in muscle and liver is a potential mechanism of enhanced insulin action. Importantly, both homozygous and heterozygous Ptp1b mice are refractory to high-fat diet-induced obesity and insulin resistance. The decreased adipose tissue mass is correlated with increased basal metabolic rate and energy expenditure (60, 124). These data suggest that Ptp1b is one of the tyrosine phosphatases required for termination of insulin action, modulation of energy expenditure, and development of adipose tissue. Therefore, inhibition of this gene product could be of significant benefit for treatment of type 2 diabetes and states of insulin resistance. In fact, treatment of diabetic (253) and obese mice (84) with antisense oligonucleotides directed against Ptp1b results in decreased protein levels and ameliorates the metabolic syndrome, paving the way for therapeutic approaches to diabetes based on inhibition of Ptp1b. activity. Based on the mechanics of the interaction between the catalytic (p110) and regulatory subunits of PI3K (196), these data are consistent with a model in which the regulatory subunits act as inhibitors of PI3K activity under basal conditions, while insulin removes this inhibition via Irs proteins. A compelling demonstration of the insulin-sensitizing effect of null p85 alleles is seen in heterozygous carriers of the mutation, when they are crossed with insulinresistant mice. Haploinsufficiency of p85 protects both Insr and Irs1 heterozyotes from insulin resistance and diabetes by improving the efficiency of insulin signaling (162). INSULIN RESISTANCE IN MICE tor (6) and is reduced in Jnk1⫺/⫺ mice (91). Thus Jnk1 appears to be one of the Irs serine kinases that are involved in downregulation of insulin signaling. E. Salicylates, Ikk, and the Metabolic Syndrome F. The Forkhead Transcription Factor Foxo1 Insight into distal effectors of insulin signaling has been gleaned from studies of the dauer phenotype in the roundworm C. elegans, a condition characterized by impaired metabolism and prolonged life span. In addition to nutritional and hormonal cues, the dauer stage can be brought about by genetic mutations in insulin signaling (79). Thus mutations of the daf2 (Insr ortholog) (118), age1 (PI3K) (166), and akt1–2 genes (180) cause dauer formation. In contrast, mutations of the daf16 gene rescue the phenotype due to daf2 mutations (151, 152, 178). The mammalian orthologs of daf16 belong to the Foxo subfamily of transcription factors (104). The prediction from the C. elegans studies was that mammalian Foxo would act as a negative regulator of insulin signaling and that loss-of-function Foxo mutations would rescue diabetes due to Insr mutations. In recent publications, Foxo1 has been shown to be a negative regulator of insulin signaling in key tissues for metabolic control. Foxo proteins are Akt substrates. Phosphorylation of key consensus Akt sites in Foxo1, -3, and -4 is associated with nuclear exclusion and suppression of their transcriptional activity (33, 129, 175). It should be emphasized that Foxo1 acts both as a promoter and a repressor of gene expression. Physiol Rev • VOL 1. Foxo1 in liver Foxo1 plays an important role in insulin control of hepatic glucose production. Evidence from studies in cultured cells indicates that Foxo1 can mediate insulin-inhibitable transcription of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase (174), acting in concert with the PPAR␥ coactivator Pgc1 (192). Haploinsufficiency of the Foxo1 gene restores insulin sensitivity and rescues the diabetic phenotype in insulin-resistant mice by reducing hepatic expression of glucogenetic genes and increasing adipocyte expression of insulin-sensitizing genes. Conversely, a gain-of-function Foxo1 mutant targeted to liver and pancreatic -cells results in diabetes arising from a combination of increased hepatic glucose production and impaired -cell compensation due to decreased Pdx1 expression (171). In addition to restoring insulin sensitivity in a genetic model of insulin resistance, Foxo1 haploinsufficiency protects from diet-induced diabetes in mice, suggesting that strategies aimed at decreasing Foxo1 levels and/or activity represent a new approach to diabetes treatment (173). 2. Foxo1 in -cells The localization of Foxo1 immunoreactivity to pancreatic -cells has led to studies of its role in terminal differentiation and proliferation in a variety of cell systems. Mice lacking Irs2 develop -cell failure, suggesting that insulin signaling is required to maintain an adequate -cell mass. Haploinsufficiency of Foxo1 reverses -cell failure in Irs2⫺/⫺ mice through partial restoration of -cell proliferation and increased expression of the pancreatic transcription factor Pdx1. Interestingly, Foxo1 and Pdx1 exhibit mutually exclusive patterns of nuclear localization in -cells, and constitutive nuclear expression of Foxo1 is associated with reduced Pdx1 expression (171). Based on the localization of Foxo1 to a subset of cells abutting pancreatic ducts, it has been suggested that insulin/IGFs regulate -cell proliferation by relieving Foxo1 inhibition of Pdx1 expression in these cells (123). The implication of these studies is that Foxo1 expression is a marker of a pancreatic cell subpopulation with the potential to give rise to mature -cells. 3. Foxo1 in adipose cells Foxo1 haploinsufficiency has been shown to decrease adipocyte size and increase expression of genes that promote lipid metabolism (173). Recent evidence indicates that the effect of Foxo1 haploinsufficiency in fat can be explained by a direct action of this transcription factor in adipocytes. In vitro studies of adipocyte differentiation indicate that Foxo1 expression is induced in the early stages of adipogenesis in 3T3-F442A cells. Interestingly, Foxo1 phosphorylation appears to be tightly regu- 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 Salicylates improve glucose disposal and increase insulin action. High-dose aspirin treatment decreases fasting plasma glucose and improves the lipid profile of type 2 diabetic patients. Euglycemic-hyperinsulinemic clamp studies indicate that the improvement is associated with a reduction of hepatic glucose output and an increase in insulin-stimulated peripheral glucose uptake (97). The mechanism by which salicylates increase insulin sensitivity has recently been elucidated in some detail using genetically engineered mice. Studies in rodents implicate activation of I kappa B kinase beta (Ikk) as a critical step in lipid-induced insulin resistance. Overexpression of Ikk in cultured cells leads to altered insulin action, whereas inhibition of this gene improves insulin resistance. Ikk knockout mice do not develop insulin resistance in the setting of a lipid infusion, while haploinsufficiency at this locus prevents peripheral insulin resistance in the setting of high-fat diet or leptin deficiency in obese mice (115, 250). These findings identify Ikk as a potential target for the treatment of insulin-resistant diabetes. 639 640 NANDI, KITAMURA, KAHN, AND ACCILI X. CONCLUSIONS The availability of techniques of targeted mutagenesis has transformed the experimental approach to metabolism. Investigators can now introduce virtually any mutation in mice and study its metabolic effects. As a result, we have begun to untangle the complex genetic pathways that regulate insulin action. In addition to establishing the role of the three receptors of the insulin family in physiology, these studies have clarified the functions of Irs and PI3K in insulin signaling. Unsuspected players, such as the Foxo transcription factors, Ceacam, Ptp-1b, Jnk1, and Ikk, have emerged from these studies. In addition, novel roles of established players, such as the insulin receptor and its substrates in pancreatic -cells and brain, are now more clearly defined. Work in the authors’ laboratory is supported by the National Institutes of Health, the Juvenile Diabetes Research Foundation, and the American Diabetes Association. Address for reprint requests and other correspondence: D. Accili, Berrie Research Pavilion, 1150 St. Nicholas Ave., New York, NY 10032 (E-mail: [email protected]). REFERENCES 1. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, Boers ME, Hadro E, ObersteBerghaus C, Quist W, Lowell BB, Ingwall JS, and Kahn BB. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104: 1703– 1714, 1999. 2. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, and Kahn BB. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409: 729 –733, 2001. 3. Accili D. A kinase in the life of the beta cell. J Clin Invest 108: 1575–1576, 2001. Physiol Rev • VOL 4. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, Asico LD, Jose PA, Taylor SI, and Westphal H. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12: 106 –109, 1996. 5. Aguirre V, Uchida T, Yenush L, Davis R, and White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047–9054, 2000. 6. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, and White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277: 1531–1537, 2002. 7. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, and Bownes M. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7: 776 –789, 1997. 8. Almind K, Frederiksen SK, Bernal D, Hansen T, Ambye L, Urhammer S, Ekstrom CT, Berglund L, Reneland R, Lithell H, White MF, Van Obberghen E, and Pedersen O. Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: evaluation of their relation with alterations in insulin secretion and insulin sensitivity. Diabetologia 42: 1244 –1249, 1999. 9. Almind K, Kulkarni RN, Lannon SM, and Kahn CR. Identification of interactive loci linked to insulin and leptin in mice with genetic insulin resistance. Diabetes 52: 1535–1543, 2003. 10. Apfeld J and Kenyon C. Cell nonautonomy of C. elegans daf-2 function in the regulation of diapause and life span. Cell 95: 199 – 210, 1998. 13. Araki E, Lipes MA, Patti ME, Bruning JC, Haag BR, Johnson RS, and Kahn CR. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372: 186 – 190, 1994. 14. Aspinwall CA, Qian WJ, Roper MG, Kulkarni RN, Kahn CR, and Kennedy RT. Roles of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and release of intracellular Ca2⫹ stores in insulin-stimulated insulin secretion in beta-cells. J Biol Chem 275: 22331–22338, 2000. 15. Backeljauw PF, Alves C, Eidson M, Cleveland W, Underwood LE, and Davenport ML. Effect of intravenous insulin-like growth factor I in two patients with leprechaunism. Pediatr Res 36: 749 – 754, 1994. 16. Baron AD. Hemodynamic actions of insulin. Am J Physiol Endocrinol Metab 267: E187–E202, 1994. 17. Baron AD, Steinberg H, Brechtel G, and Johnson A. Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am J Physiol Endocrinol Metab 266: E248 –E253, 1994. 18. Barrett CT and Oliver TK Jr. Hypoglycemia and hyperinsulinism in infants with erythroblastosis fetalis. N Engl J Med 278: 1260 – 1262, 1968. 19. Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S, Bickel PE, Pessin JE, and Saltiel AR. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407: 202–207, 2000. 20. Bektas A, Warram JH, White MF, Krolewski AS, and Doria A. Exclusion of insulin receptor substrate 2 (IRS-2) as a major locus for early-onset autosomal dominant type 2 diabetes. Diabetes 48: 640 – 642, 1999. 21. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, and Abel ED. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 109: 629 – 639, 2002. 22. Bell GI and Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 414: 788 –791, 2001. 23. Bernal D, Almind K, Yenush L, Ayoub M, Zhang Y, Rosshani L, Larsson C, Pedersen O, and White MF. Insulin receptor substrate-2 amino acid polymorphisms are not associated with random type 2 diabetes among Caucasians. Diabetes 47: 976 –979, 1998. 24. Bernal-Mizrachi E, Wen W, Stahlhut S, Welling C, and Per- 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 lated (173) in a manner that is consistent with the time course of PI3K activity during adipocyte differentiation (202). Expression of a phosphorylation-defective Foxo1 prevents adipocyte differentiation by altering expression patterns of genes involved in cell cycle control and adipogenesis. In contrast, a dominant negative Foxo1 restores adipocyte differentiation of murine embryonic fibroblasts from insulin receptor-deficient mice. The ability of Foxo1 to control adipogenesis may depend on its regulation of genes involved in cell cycle control, such as p21 and the retinoblastoma gene product (173). Thus the emerging model of Foxo1 function in fat cells is that it may control the coupling of extracellular (hormonal) cues that activate adipocyte differentiation to the cell cycle machinery, thus providing the integration of hormoneactivated signaling pathways with the transcriptional cascade that promotes adipogenesis (173). A similar paradigm appears to be at play in myoblast differentiation in response to IGFs (94). INSULIN RESISTANCE IN MICE 25. 26. 27. 28. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. Physiol Rev • VOL 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. mans S. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409: 92–97, 2001. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 140: 19 –24, 1998. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, and Shulman GI. Impaired glucose transport as a cause of decreased insulinstimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341: 240 –246, 1999. Cox NJ, Frigge M, Nicolae DL, Concannon P, Hanis CL, Bell GI, and Kong A. Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. Nat Genet 21: 213–215, 1999. Cross DA, Alessi DR, Cohen P, Andjelkovich M, and Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785–789, 1995. Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, and Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care 22: 944 –950, 1999. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, and Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J 290: 811– 815, 1985. Datta SR, Brunet A, and Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 13: 2905–2927, 1999. DeBaun MR, King AA, and White N. Hypoglycemia in BeckwithWiedemann syndrome. Semin Perinatol 24: 164 –171, 2000. DeChiara TM, Efstratiadis A, and Robertson EJ. A growthdeficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345: 78 – 80, 1990. De Fea K and Roth RA. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. Biochemistry 36: 12939 –12947, 1997. Desbois-Mouthon C, Magre J, Duprey J, Caron M, Blivet-Van Eggelpoel MJ, Daubas C, Gourmelen M, Chevallier B, Rizkalla S, Robert JJ, and Capeau J. Major circadian variations of glucose homeostasis in a patient with Rabson-Mendenhall syndrome and primary insulin resistance due to a mutation (Cys2843 Tyr) in the insulin receptor alpha-subunit. Pediatr Res 42: 72–77, 1997. Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pelegrin M, Gros L, and Bosch F. Transgenic mice overexpressing insulinlike growth factor-II in beta cells develop type 2 diabetes. J Clin Invest 105: 731–740, 2000. Di Cola G, Cool MH, and Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 99: 2538 –2544, 1997. Duvillie B, Cordonnier N, Deltour L, Dandoy-Dron F, Itier JM, Monthioux E, Jami J, Joshi RL, and Bucchini D. Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci USA 94: 5137–5140, 1997. Economides DL, Nicolaides KH, and Campbell S. Metabolic and endocrine findings in appropriate and small for gestational age fetuses. J Perinat Med 19: 97–105, 1991. Efstratiadis A. Genetics of mouse growth. Int J Dev Biol 42: 955–976, 1998. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, and Kennedy BP. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283: 1544 –1548, 1999. Eto K, Yamashita T, Tsubamoto Y, Terauchi Y, Hirose K, Kubota N, Yamashita S, Taka J, Satoh S, Sekihara H, Tobe K, Iino M, Noda M, Kimura S, and Kadowaki T. Phosphatidylinositol 3-kinase suppresses glucose-stimulated insulin secretion by affecting post-cytosolic [Ca(2⫹)] elevation signals. Diabetes 51: 87–97, 2002. Fantin VR, Wang Q, Lienhard GE, and Keller SR. Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, repro- 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 29. mutt M. Transgenic mice expressing a constitutively active Akt1/ PKB␣ in pancreatic islet -cells exhibit striking hypertrophy, hyperplasia and hyperinsulinemia. J Clin Invest 108: 1631–1638, 2001. Bier DM, Schedewie H, Larner J, Olefsky J, Rubenstein A, Fiser RH, Craig JW, and Elders MJ. Glucose kinetics in leprechaunism: accelerated fasting due to insulin resistance. J Clin Endocrinol Metab 51: 988 –994, 1980. Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, and Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96: 7421–7426, 1999. Bjornholm M, He AR, Attersand A, Lake S, Liu SC, Lienhard GE, Taylor S, Arner P, and Zierath JR. Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans. Diabetologia 45: 1697–1702, 2002. Bluher M, Kahn BB, and Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299: 572–574, 2003. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, and Kahn CR. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3: 25–38, 2002. Bocian-Sobkowska J, Zabel M, Wozniak W, and SurdykZasada J. Polyhormonal aspect of the endocrine cells of the human fetal pancreas. Histochem Cell Biol 112: 147–153, 1999. Bonadonna RC, Saccomani MP, Del Prato S, Bonora E, DeFronzo RA, and Cobelli C. Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation 98: 234 –241, 1998. Bose A, Guilherme A, Robida SI, Nicoloro SM, Zhou QL, Jiang ZY, Pomerleau DP, and Czech MP. Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c. Nature 420: 821– 824, 2002. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, and Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96: 857– 868, 1999. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, and Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. Science 289: 2122–2155, 2000. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, Goodyear LJ, and Kahn CR. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2: 559 –569, 1998. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, and Kahn CR. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88: 561–572, 1997. Burgering BM and Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599 – 602, 1995. Burks DJ, de Mora JF, Schubert M, Withers DJ, Myers MG, Towery HH, Altamuro SL, Flint CL, and White MF. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 407: 377–382, 2000. Burks DJ and White MF. IRS proteins and beta-cell function. Diabetes 50 Suppl 1: S140 –S145, 2001. Cherrington Banting Lecture 1997 AD. Control of glucose uptake and release by the liver in vivo. Diabetes 48: 1198 –1214, 1999. Chiang SH, Baumann CA, Kanzaki M, Thurmond DC, Watson RT, Neudauer CL, Macara IG, Pessin JE, and Saltiel AR. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410: 944 –948, 2001. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd Kaestner KH, Bartolomei MS, Shulman GI, and Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292: 1728 –1731, 2001. Clement S, Krause U, Desmedt F, Tanti JF, Behrends J, Pesesse X, Sasaki S, Penninger P, Doherty M, Malaisse W, Dumont J, Le Marchand-Brustel Y, Erneux C, Hue L, and Schur- 641 642 63. 64. 65. 66. 67. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. duction, and glucose homeostasis. Am J Physiol Endocrinol Metab 278: E127–E133, 2000. Fernandez A, Kim J, Yakar S, Dupont J, Hernandez-Sanchez C, Castle A, Filmore J, Shulman G, and Le Roith D. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15: 1926 –1934, 2001. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Baldi S, Frascerra S, Monzani F, Antonelli A, Nannipieri M, Mari A, Seghieri G, and Natali A. Insulin: new roles for an ancient hormone. Eur J Clin Invest 29: 842– 852, 1999. Finegood DT, Scaglia L, and Bonner-Weir S. Dynamics of betacell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 44: 249 –256, 1995. Fisher SJ and Kahn CR. Insulin signaling is required for insulin’s direct and indirect action on hepatic glucose production. J Clin Invest 111: 463– 468, 2003. Flier SN, Kulkarni RN, and Kahn CR. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc Natl Acad Sci USA 98: 7475–7480, 2001. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, and Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19: 3278 – 3288, 1999. Freidenberg GR, Reichart D, Olefsky JM, and Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. J Clin Invest 82: 1398 –1406, 1988. Fruman DA, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, Bronson RT, Kahn CR, and Cantley LC. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85alpha. Nat Genet 26: 379 –382, 2000. Frystyk J, Grofte T, Skjaerbaek C, and Orskov H. The effect of oral glucose on serum free insulin-like growth factor-I and -II in health adults. J Clin Endocrinol Metab 82: 3124 –3127, 1997. Frystyk J, Gronbaek H, Skjaerbaek C, Flyvbjerg A, Orskov H, and Baxter RC. Developmental changes in serum levels of free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit in rats. Endocrinology 139: 4286 – 4292, 1998. Garcia-Ocana A, Takane KK, Syed MA, Philbrick WM, Vasavada RC, and Stewart AF. Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J Biol Chem 275: 1226 –1232, 2000. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, McNeish JD, and Coleman KG. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 112: 197–208, 2003. Ghosh S and Collins FS. The geneticist’s approach to complex disease. Annu Rev Med 47: 333–353, 1996. Girard J, Ferre P, Pegorier JP, and Duee PH. Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition. Physiol Rev 72: 507–562, 1992. Girard JR, Kervan A, Soufflet E, and Assan R. Factors affecting the secretion of insulin and glucagon by the rat fetus. Diabetes 23: 310 –317, 1973. Golay A, DeFronzo RA, Ferrannini E, Simonson DC, Thorin D, Acheson K, Thiebaud D, Curchod B, Jequier E, and Felber JP. Oxidative and non-oxidative glucose metabolism in non-obese type 2 (non-insulin-dependent) diabetic patients. Diabetologia 31: 585–591, 1988. Gottlieb S and Ruvkun G. daf-2, daf-16 and daf-23: genetically interacting genes controlling Dauer formation in Caenorhabditis elegans. Genetics 137: 107–120, 1994. Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, and Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell 83: 69 –78, 1995. Guarente L, Ruvkun G, and Amasino R. Aging, life span, and senescence. Proc Natl Acad Sci USA 95: 11034 –11036, 1998. Guerra C, Navarro P, Valverde AM, Arribas M, Bruning J, Physiol Rev • VOL 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. Kozak LP, Kahn CR, and Benito M. Brown adipose tissuespecific insulin receptor knockout shows diabetic phenotype without insulin resistance. J Clin Invest 108: 1205–1213, 2001. Guillam MT, Hummler E, Schaerer E, Yeh JI, Birnbaum MJ, Beermann F, Schmidt A, Deriaz N, Thorens B, and Wu JY. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet 17: 327–330, 1997. Gum RJ, Gaede LL, Koterski SL, Heindel M, Clampit JE, Zinker BA, Trevillyan JM, Ulrich RG, Jirousek MR, and Rondinone CM. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 52: 21–28, 2003. Han VK, D’Ercole AJ, and Lund PK. Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 236: 193–197, 1987. Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD, and Ron D. Diabetes mellitus and exocrine pancreatic dysfunction in perk⫺/⫺ mice reveals a role for translational control in secretory cell survival. Mol Cell 7: 1153–1163, 2001. Havrankova J, Roth J, and Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272: 827– 829, 1978. Hazeltine FG. Hypoglycemia and RH erythroblastosis fetalis. Pediatrics 39: 696 – 699, 1967. Herrera PL, Huarte J, Sanvito F, Meda P, Orci L, and Vassalli JD. Embryogenesis of the murine endocrine pancreas: early expression of pancreatic polypeptide gene. Development 113: 1257– 1265, 1991. Hirayama I, Tamemoto H, Yokota H, Kubo SK, Wang J, Kuwano H, Nagamachi Y, Takeuchi T, and Izumi T. Insulin receptor-related receptor is expressed in pancreatic beta-cells and stimulates tyrosine phosphorylation of insulin receptor substrate-1 and -2. Diabetes 48: 1237–1244, 1999. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, and Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 420: 333–336, 2002. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, and Wong AJ. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 379: 560 –564, 1996. Hone J, Accili D, Psiachou H, Alghband ZJ, Mitton S, Wertheimer E, Sinclair L, and Taylor SI. Homozygosity for a null allele of the insulin receptor gene in a patient with leprechaunism. Hum Mutat 6: 17–22, 1995. Hribal ML, Nakae J, Kitamura T, Shutter JR, and Accili D. Regulation of insulin-like growth factor-dependent myoblast differentiation by Foxo forkhead transcription factors. J Cell Biol 162: 535–541, 2003. Hribal ML, Oriente F, and Accili D. Mouse models of insulin resistance. Am J Physiol Endocrinol Metab 282: E977–E981, 2002. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, and Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 285: H1261–H1269, 2003. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, and Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109: 1321–1326, 2002. Isakoff SJ, Taha C, Rose E, Marcusohn J, Klip A, and Skolnik EY. The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake. Proc Natl Acad Sci USA 92: 10247–10251, 1995. Jiang ZY, Chawla A, Bose A, Way M, and Czech MP. A phosphatidylinositol 3-kinase-independent insulin signaling pathway to N-WASP/Arp2/3/F-actin required for GLUT4 glucose transporter recycling. J Biol Chem 277: 509 –515, 2002. Joost HG, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S, Schurmann A, Seino S, and Thorens B. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282: E974 –E976, 2002. Joshi RL, Lamothe B, Cordonnier N, Mesbah K, Monthioux E, Jami J, and Bucchini D. Targeted disruption of the insulin recep- 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 68. NANDI, KITAMURA, KAHN, AND ACCILI INSULIN RESISTANCE IN MICE 102. 103. 104. 105. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. Physiol Rev • VOL 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. Lipoatrophy, postnatal growth retardation and diabetes resulting from variable conditional inactivation of the insulin receptor gene in mice (Abstract). Diabetes 51 Suppl 2: 1337, 2002. Kitamura T, Nakae J, Kitamura Y, Kido Y, Biggs WH III, Wright CV, White MF, Arden KC, and Accili D. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 110: 1839 –1847, 2002. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, StrickerKrongrad A, Shulman GI, Neel BG, and Kahn BB. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20: 5479 –5489, 2000. Kohn AD, Barthel A, Kovacina KS, Boge A, Wallach B, Summers SA, Birnbaum MJ, Scott PH, Lawrence JC Jr, and Roth RA. Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J Biol Chem 273: 11937– 11943, 1998. Kohn AD, Summers SA, Birnbaum MJ, and Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3–L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271: 31372–31378, 1996. Kohn AD, Takeuchi F, and Roth RA. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem 271: 21920 –21926, 1996. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, and Kahn CR. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 111: 1835–1842, 2003. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, and Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398: 630 – 634, 1999. Kotani K, Ogawa W, Matsumoto M, Kitamura T, Sakaue H, Hino Y, Miyake K, Sano W, Akimoto K, Ohno S, and Kasuga M. Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for akt activation in 3T3–L1 adipocytes. Mol Cell Biol 18: 6971– 6982, 1998. Krook A, Brueton L, and O’Rahilly S. Homozygous nonsense mutation in the insulin receptor gene in infant with leprechaunism. Lancet 342: 277–278, 1993. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H, Satoh S, Sekihara H, Sciacchitano S, Lesniak M, Aizawa S, Nagai R, Kimura S, Akanuma Y, Taylor SI, and Kadowaki T. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 49: 1880 –1889, 2000. Kulkarni RN, Almind K, Goren HJ, Winnay JN, Ueki K, Okada T, and Kahn CR. Impact of genetic background on development of hyperinsulinemia and diabetes in insulin receptor/insulin receptor substrate-1 double heterozygous mice. Diabetes 52: 1528 –1534, 2003. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, and Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96: 329 –339, 1999. Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, Magnuson MA, and Kahn CR. Beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 31: 111–115, 2002. Kulkarni RN, Michael MD, and Kahn CR. Tissue-specific knockouts of the insulin receptor tyrosine kinase. In: Genetic Manipulation of Receptor Expression and Function, edited by Accili D. New York: Wiley, 2000, p. 129 –154. Kulkarni RN, Winnay JN, Daniels M, Bruning JC, Flier SN, Hanahan D, and Kahn CR. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Invest 104: R69 –R75, 1999. Kushner JA, Ye J, Schubert M, Burks DJ, Dow MA, Flint CL, Dutta S, Wright CV, Montminy MR, and White MF. Pdx1 restores beta cell function in Irs2 knockout mice. J Clin Invest 109: 1193–1201, 2002. 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 106. tor gene in the mouse results in neonatal lethality. EMBO J 15: 1542–1547, 1996. Jospe N, Kaplowitz PB, and Furlanetto RW. Homozygous nonsense mutation in the insulin receptor gene of a patient with severe congenital insulin resistance: leprechaunism and the role of the insulin-like growth factor receptor. Clin Endocrinol 45: 229 –235, 1996. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, and Taylor SI. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 240: 787–790, 1988. Kaestner KH, Knochel W, and Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 14: 142–146, 2000. Kanety H, Feinstein R, Papa MZ, Hemi R, and Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 270: 23780 –23784, 1995. Katz EB, Stenbit AE, Hatton K, DePinho R, and Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377: 151–155, 1995. Kaur J, Singh P, and Sowers JR. Diabetes and cardiovascular diseases. Am J Ther 9: 510 –515, 2002. Kenyon C. A conserved regulatory system for aging. Cell 105: 165–168, 2001. Kervran A and Girard JR. Glucose induced increase of plasma insulin in the rat fetus in utero. J Endocrinol 62: 545–551, 1974. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF, and Accili D. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 105: 199 –205, 2000. Kido Y, Nakae J, and Accili D. Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab 86: 972–979, 2001. Kido Y, Nakae J, Hribal ML, Xuan S, Efstratiadis A, and Accili D. Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem 277: 36740 –36747, 2002. Kim J and Accili D. Signalling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res 12: 84, 2002. Kim JJ, Park BC, Kido Y, and Accili D. Mitogenic and metabolic effects of type I IGF receptor overexpression in insulin receptordeficient hepatocytes. Endocrinology 142: 3354 –3360, 2001. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, and Shulman GI. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108: 437– 446, 2001. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S, Kahn BB, Kahn CR, and Shulman GI. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 105: 1791–1797, 2000. Kim JK, Zisman A, Fillmore JJ, Peroni OD, Kotani K, Perret P, Zong H, Dong J, Kahn CR, Kahn BB, and Shulman GI. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 108: 153–160, 2001. Kimura KD, Tissenbaum HA, Liu Y, and Ruvkun G. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277: 942–946, 1997. King GL and Johnson SM. Receptor-mediated transport of insulin across endothelial cells. Science 227: 1583–1586, 1985. Kitamura T, Kido Y, Nef S, Merenmies J, Parada LF, and Accili D. Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor. Mol Cell Biol 21: 5624 –5630, 2001. Kitamura T, Kitamura Y, Kuroda S, Hino Y, Ando M, Kotani K, Konishi H, Matsuzaki H, Kikkawa U, Ogawa W, and Kasuga M. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol 19: 6286 – 6296, 1999. Kitamura T, Nakae J, Kahn C, Efstratiadis A, and Accili D. 643 644 NANDI, KITAMURA, KAHN, AND ACCILI Physiol Rev • VOL 160. Marin P, Hogh-Kristiansen I, Jansson S, Krotkiewski M, Holm G, and Bjorntorp P. Uptake of glucose carbon in muscle glycogen and adipose tissue triglycerides in vivo in humans. Am J Physiol Endocrinol Metab 263: E473–E480, 1992. 161. Matschinsky Banting Lecture 1995 FM. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45: 223–241, 1996. 162. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, and Kahn CR. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109: 141–149, 2002. 163. Mc Evoy RC and Madson KL. Pancreatic insulin-, glucagon-, and somatostatin-positive islets cell populations during the perinatal development of the rat. II. Changes in hormone content and concentration. Biol Neonate 38: 255–259, 1980. 164. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, and Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6: 87–97, 2000. 165. Miki H, Yamauchi T, Suzuki R, Komeda K, Tsuchida A, Kubota N, Terauchi Y, Kamon J, Kaburagi Y, Matsui J, Akanuma Y, Nagai R, Kimura S, Tobe K, and Kadowaki T. Essential role of insulin receptor substrate 1 (IRS-1) and IRS-2 in adipocyte differentiation. Mol Cell Biol 21: 2521–2532, 2001. 166. Morris JZ, Tissenbaum HA, and Ruvkun G. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382: 536 –539, 1996. 167. Mu J, Brozinick JT Jr, Valladares O, Bucan M, and Birnbaum MJ. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7: 1085–1094, 2001. 168. Najjar SM, Blakesley VA, Li Calzi S, Kato H, LeRoith D, and Choice CV. Differential phosphorylation of pp120 by insulin and insulin-like growth factor-1 receptors: role for the C-terminal domain of the beta-subunit. Biochemistry 36: 6827– 6834, 1997. 169. Najjar SM, Philippe N, Suzuki Y, Ignacio GA, Formisano P, Accili D, and Taylor SI. Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. Biochemistry 34: 9341–9349, 1995. 170. Nakae J, Barr V, and Accili D. Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J 19: 989 –996, 2000. 171. Nakae J, Biggs WH, Kitamura T, Cavenee WK, Wright CV, Arden KC, and Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 32: 245–253, 2002. 172. Nakae J, Kido Y, and Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22: 818 – 835, 2001. 173. Nakae J, Kitamura T, Kitamura Y, Biggs WH, Arden KC, and Accili D. The forkhead transcription factor foxo1 regulates adipocyte differentiation. Dev Cell 4: 119 –129, 2003. 174. Nakae J, Kitamura T, Silver DL, and Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 108: 1359 –1367, 2001. 175. Nakae J, Park BC, and Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a wortmannin-sensitive pathway. J Biol Chem 274: 15982– 15985, 1999. 176. Obici S, Feng Z, Karkanias G, Baskin DG, and Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 5: 566 –572, 2002. 177. Obici S, Zhang BB, Karkanias G, and Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8: 1376 –1382, 2002. 178. Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, and Ruvkun G. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389: 994 –999, 1997. 179. Olefsky JM, Kolterman OG, and Scarlett JA. Insulin action and 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 139. Lander ES and Schork NJ. Genetic dissection of complex traits. Science 265: 2037–2048, 1994. 140. Lauro D, Kido Y, Castle AL, Zarnowski MJ, Hayashi H, Ebina Y, and Accili D. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat Genet 20: 294 –298, 1998. 141. Laustsen PG, Michael MD, Crute BE, Cohen SE, Ueki K, Kulkarni RN, Keller SR, Lienhard GE, and Kahn CR. Lipoatrophic diabetes in Irs1(⫺/⫺)/Irs3(⫺/⫺) double knockout mice. Genes Dev 16: 3213–3222, 2002. 142. Lavan BE, Fantin VR, Chang ET, Lane WS, Keller SR, and Lienhard GE. A novel 160-kDa phosphotyrosine protein in insulintreated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem 272: 21403–21407, 1997. 143. Lavan BE, Lane WS, and Lienhard GE. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 272: 11439 –11443, 1997. 144. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, Prescott AR, Lucocq JM, and Alessi DR. Essential role of PDK1 in regulating cell size and development in mice. EMBO J 21: 3728 –3738, 2002. 145. Leahy JL and Vandekerkhove KM. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 126: 1593–1598, 1990. 146. Lee SS and Ruvkun G. Longevity: don’t hold your breath. Nature 418: 287–288, 2002. 147. Leibiger B, Leibiger IB, Moede T, Kemper S, Kulkarni RN, Kahn CR, de Vargas LM, and Berggren P. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells. Mol Cell 7: 559 –570, 2001. 148. Leibiger IB, Leibiger B, Moede T, and Berggren PO. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. Mol Cell 1: 933–938, 1998. 149. Leslie NR, Biondi RM, and Alessi DR. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem Rev 101: 2365–2380, 2001. 150. Like AA and Orci L. Embryogenesis of the human pancreatic islets: a light and electron microscopic study. Diabetes 21: 511–534, 1972. 151. Lin K, Dorman JB, Rodan A, and Kenyon C. daf-16: an HNF-3/ forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science 278: 1319 –1322, 1997. 152. Lin K, Hsin H, Libina N, and Kenyon C. Regulation of the Caenorhabditis elegans longevity protein DAF-16 by insulin/IGF-1 and germline signaling. Nat Genet 28: 139 –145, 2001. 153. Liu JP, Baker J, Perkins AS, Robertson EJ, and Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75: 59 –72, 1993. 154. Liu SCH, Wang Q, Lienhard GE, and Keller SR. Insulin receptor substrate 3 is not essential for growth or glucose homeostasis. J Biol Chem 274: 18093–18099, 1999. 155. Longo N, Wang Y, and Pasquali M. Progressive decline in insulin levels in Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 84: 2623–2629, 1999. 156. Louvi A, Accili D, and Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol 189: 33– 48, 1997. 157. Lowell BB, SSV, Hamann A, Lawitts JA, Himms HJ, Boyer BB, Kozak LP, and Flier JS. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366: 740 –742, 1993. 158. Ludwig T, Eggenschwiler J, Fisher P, D’Ercole AJ, Davenport ML, and Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 177: 517–535, 1996. 159. Lund PK, Moats-Staats BM, Hynes MA, Simmons JG, Jansen M, D’Ercole AJ, and Van Wyk JJ. Somatomedin-C/insulin-like growth factor-I and insulin-like growth factor-II mRNAs in rat fetal and adult tissues. J Biol Chem 261: 14539 –14544, 1986. INSULIN RESISTANCE IN MICE 180. 181. 182. 183. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. Physiol Rev • VOL 199. Rother KI, Imai Y, Caruso M, Beguinot F, Formisano P, and Accili D. Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem 273: 17491–17497, 1998. 200. Roysarkar TK, Gupta A, Dash RJ, and Dogra MR. Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes mellitus. Am J Ophthalmol 115: 569 –574, 1993. 201. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, and White MF. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107: 181–189, 2001. 202. Sakaue H, Ogawa W, Matsumoto M, Kuroda S, Takata M, Sugimoto T, Spiegelman BM, and Kasuga M. Posttranscriptional control of adipocyte differentiation through activation of phosphoinositide 3-kinase. J Biol Chem 273: 28945–28952, 1998. 203. Saltiel AR and Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799 – 806, 2001. 204. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, Saunders T, Bonner-Weir S, and Kaufman RJ. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 7: 1165–1176, 2001. 205. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, and Baskin DG. Central nervous system control of food intake. Nature 404: 661– 671, 2000. 206. Sciacchitano S and Taylor SI. Cloning, tissue expression, and chromosomal localization of the mouse IRS-3 gene. Endocrinology 138: 4931– 4940, 1997. 207. She P, Shiota M, Shelton KD, Chalkley R, Postic C, and Magnuson MA. Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism. Mol Cell Biol 20: 6508 – 6517, 2000. 208. Shefi-Friedman L, Wertheimer E, Shen S, Bak A, Accili D, and Sampson SR. Increased IGFR activity and glucose transport in cultured skeletal muscle from insulin receptor null mice. Am J Physiol Endocrinol Metab 281: E16 –E24, 2001. 209. Shier P and Watt VM. Primary structure of a putative receptor for a ligand of the insulin family. J Biol Chem 264: 14605–14608, 1989. 210. Shimizu Y and Shimazu T. Effects of wortmannin on increased glucose transport by insulin and norepinephrine in primary culture of brown adipocytes. Biochem Biophys Res Commun 202: 660 – 665, 1994. 211. Shiojima I, Yefremashvili M, Luo Z, Kureishi Y, Takahashi A, Tao J, Rosenzweig A, Kahn CR, Abel ED, and Walsh K. Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem 277: 37670 –37677, 2002. 212. Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis B, and Schlessinger J. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 260: 1953–1955, 1993. 213. Smith-Hall J, Pons S, Patti ME, Burks DJ, Yenush L, Sun XJ, Kahn CR, and White MF. The 60 kDa insulin receptor substrate functions like an IRS protein (pp60IRS3) in adipose cells. Biochemistry 36: 8304 – 8310, 1997. 214. Standaert ML, Bandyopadhyay G, Galloway L, Soto J, Ono Y, Kikkawa U, Farese RV, and Leitges M. Effects of knockout of the protein kinase C beta gene on glucose transport and glucose homeostasis. Endocrinology 140: 4470 – 4477, 1999. 215. Stefan Y, Ravazzola M, and Orci L. Primitive islets contain two populations of cells with differing glucagon immunoreactivity. Diabetes 30: 192–195, 1981. 216. Steil GM, Ader M, Moore DM, Rebrin K, and Bergman RN. Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process. J Clin Invest 97: 1497– 1503, 1996. 217. Stenbit AE, Tsao TS, Li J, Burcelin R, Geenen DL, Factor SM, Houseknecht K, Katz EB, and Charron MJ. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 3: 1096 –1101, 1997. 218. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, and White MF. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352: 73–77, 1991. 219. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MJ, Glasheen E, 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 184. resistance in obesity and noninsulin-dependent type II diabetes mellitus. Am J Physiol Endocrinol Metab 243: E15–E30, 1982. Paradis S and Ruvkun G. Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes Dev 12: 2488 –2498, 1998. Park BC, Kido Y, and Accili D. Differential signaling of insulin and IGF-1 receptors to glycogen synthesis in murine hepatocytes. Biochemistry 38: 7517–7523, 1999. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, and Zick Y. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272: 29911–29918, 1997. Pendergrass M, Fazioni E, and DeFronzo RA. Non-insulindependent diabetes mellitus and gestational diabetes mellitus: same disease, another name? Diabetes Rev 3: 566 –583, 1996. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG, and Hay N. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17: 1352–1365, 2003. Polak M, Bouchareb-Banaei L, Scharfmann R, and Czernichow P. Early pattern of differentiation in the human pancreas. Diabetes 49: 225–232, 2000. Polonsky KS, Sturis J, and Bell GI. Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334: 777–783, 1996. Postic C and Magnuson MA. DNA excision in liver by an albuminCre transgene occurs progressively with age. Genesis 26: 149 –150, 2000. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, and Magnuson MA. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274: 305–315, 1999. Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, Erickson SK, and Najjar SM. CEACAM1 regulates insulin clearance in liver. Nat Genet 30: 270 –276, 2002. Previs SF, Withers DJ, Ren JM, White MF, and Shulman GI. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 275: 38990 – 38994, 2000. Psiachou H, Mitton S, Alaghband ZJ, Hone J, Taylor SI, and Sinclair L. Leprechaunism and homozygous nonsense mutation in the insulin receptor gene. Lancet 342: 924, 1993. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D, and Spiegelman BM. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423: 550 –555, 2003. Rall LB, Pictet RL, and Rutter WJ. Synthesis and accumulation of proinsulin and insulin during development of the embryonic rat pancreas. Endocrinology 105: 835– 841, 1979. Reinecke-Luthge A, Koschoreck F, and Kloppel G. The molecular basis of persistent hyperinsulinemic hypoglycemia of infancy and its pathologic substrates. Virchows Arch 436: 1–5, 2000. Roach P, Zick Y, Formisano P, Accili D, Taylor SI, and Gorden P. A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing. Diabetes 43: 1096 –1102, 1994. Rordorf NT, Van HD, Chen D, White MF, and Backer JM. Regulation of phosphatidylinositol 3⬘-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J Biol Chem 270: 3662–3666, 1995. Rosen ED, Walkey CJ, Puigserver P, and Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 14: 1293– 1307, 2000. Rossetti L, Lee YT, Ruiz J, Aldridge SC, Shamoon H, and Boden G. Quantitation of glycolysis and skeletal muscle glycogen synthesis in humans. Am J Physiol Endocrinol Metab 265: E761– E769, 1993. 645 646 NANDI, KITAMURA, KAHN, AND ACCILI Physiol Rev • VOL 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503–2512, 1986. Vanhaesebroeck B and Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346: 561–576, 2000. Vasavada R, Garcia-Ocana A, Zawalich W, Dann P, Sorenson R, Ogren L, Talamantes F, and Stewart A. Expression of placental lactogen in the islets of transgenic mice results in accelerated beta cell proliferation, islet mass augmentation and hypoglycemia. Diabetes 48 Suppl 1: 245, 1999. Vasavada RC, Garcia-Ocana A, Zawalich WS, Sorenson RL, Dann P, Syed M, Ogren L, Talamantes F, and Stewart AF. Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia. J Biol Chem 275: 15399 –15406, 2000. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, and Kahn CR. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 111: 1373–1380, 2003. Wertheimer E, Lu SP, Backeljauw PF, Davenport ML, and Taylor SI. Homozygous deletion of the human insulin receptor gene results in leprechaunism. Nat Genet 5: 71–73, 1993. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin and interleukin signalling. Mol Cell Biochem 182: 3–11, 1998. Widdowson EM. Chemical composition of newly born mammals. Nature 166: 626 – 628, 1950. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, and White MF. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nature Genet 23: 32– 40, 1999. Withers DJ, Sanchez-Gutierrez J, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, BonnerWeir S, and White MF. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391: 900 –904, 1998. Wojtaszewski JF, Higaki Y, Hirshman MF, Michael MD, Dufresne SD, Kahn CR, and Goodyear LJ. Exercise modulates postreceptor insulin signaling and glucose transport in musclespecific insulin receptor knockout mice. J Clin Invest 104: 1257– 1264, 1999. Xu P, Jacobs AR, and Taylor SI. Interaction of insulin receptor substrate 3 with insulin receptor, insulin receptor-related receptor, insulin-like growth factor-1 receptor, and downstream signaling proteins. J Biol Chem 274: 15262–15270, 1999. Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE, Morroni M, Cinti S, White MF, Herrera PL, Accili D, and Efstratiadis A. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 110: 1011–1019, 2002. Yang C, Coker KJ, Kim JK, Mora S, Thurmond DC, Davis AC, Yang B, Williamson RA, Shulman GI, and Pessin JE. Syntaxin 4 heterozygous knockout mice develop muscle insulin resistance. J Clin Invest 107: 1311–1318, 2001. Yang YJ, Hope ID, Ader M, and Bergman RN. Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest 84: 1620 –1628, 1989. Yoshinari M and Daikoku S. Ontogenetic appearance of immunoreactive endocrine cells in rat pancreatic islets. Anat Embryol 165: 63–70, 1982. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, and Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277: 50230 –50236, 2002. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, and Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293: 1673–1677, 2001. Zawalich WS and Zawalich KC. A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats. Endocrinology 141: 3287–3295, 2000. 84 • APRIL 2004 • www.prv.org Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 Lane WS, Pierce JH, and White MF. Role of IRS-2 in insulin and cytokine signalling. Nature 377: 173–177, 1995. 220. Takahashi Y, Kadowaki H, Momomura K, Fukushima Y, Orban T, Okai T, Taketani Y, Akanuma Y, Yazaki Y, and Kadowaki T. A homozygous kinase-defective mutation in the insulin receptor gene in a patient with leprechaunism. Diabetologia 40: 412– 420, 1997. 221. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, and Aizawa S. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372: 182– 186, 1994. 222. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41: 1473–1490, 1992. 223. Taylor SI, Hedo JA, Underhill LH, Kasuga M, Elders MJ, and Roth J. Extreme insulin resistance in association with abnormally high binding affinity of insulin receptors from a patient with leprechaunism: evidence for a defect intrinsic to the receptor. J Clin Endocrinol Metab 55: 1108 –1113, 1982. 224. Terauchi Y, Matsui J, Suzuki R, Kubota N, Komeda K, Aizawa S, Eto K, Kimura S, Nagai R, Tobe K, Lienhard GE, and Kadowaki T. Impact of genetic background and ablation of insulin receptor substrate (IRS)-3 on IRS-2 knock-out mice. J Biol Chem 278: 14284 –14290, 2003. 225. Terauchi Y, Sakura H, Yasuda K, Iwamoto K, Takahashi N, Ito K, Kasai H, Suzuki H, Ueda O, Kamada N, Jishage K, Komeda K, Noda M, Kanazawa Y, Taniguchi S, Miwa I, Akanuma Y, Kodama T, Yazaki Y, and Kadowaki T. Pancreatic beta-cellspecific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem 270: 30253–30256, 1995. 226. Terauchi Y, Tsuji Y, Satoh S, Minoura H, Murakami K, Okuno A, Inukai K, Asano T, Kaburagi Y, Ueki K, Nakajima H, Hanafusa T, Matsuzawa Y, Sekihara H, Yin Y, Barrett JC, Oda H, Ishikawa T, Akanuma Y, Komuro I, Suzuki M, Yamamura K, Kodama T, Suzuki H, and Kadowaki T. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 21: 230 –235, 1999. 226a.The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381–389, 2000. 226b.The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 329: 977–986, 1993. 227. Tian R and Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 103: 2961–2966, 2001. 228. Tissenbaum HA and Ruvkun G. An insulin-like signaling pathway affects both longevity and reproduction in Caenorhabditis elegans. Genetics 148: 703–717, 1998. 229. Tong P, Khayat ZA, Huang C, Patel N, Ueyama A, and Klip A. Insulin-induced cortical actin remodeling promotes GLUT4 insertion at muscle cell membrane ruffles. J Clin Invest 108: 371–381, 2001. 230. Tuttle RL, Gill NS, Pugh W, Lee JP, Koeberlein B, Furth EE, Polonsky KS, Naji A, and Birnbaum MJ. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med 7: 1133–1137, 2001. 231. Tyrala EE. The infant of the diabetic mother. Obstet Gynecol Clin North Am 23: 221–241, 1996. 232. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen OM, and Ramachandran J. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313: 756 –761, 1985. 233. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, and Fujita-Yamaguchi Y. Insulin- INSULIN RESISTANCE IN MICE 252. Zhao AZ, Zhao H, Teague J, Fujimoto W, and Beavo JA. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94: 3223–3228, 1997. 253. Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, Xie N, Wilcox D, Jacobson P, Frost L, Kroeger PE, Reilly RM, Koterski S, Opgenorth TJ, Ulrich RG, Crosby S, Butler M, Murray SF, McKay RA, Bhanot S, Monia BP, and Jirousek MR. PTP1B antisense oligonucleotide 647 lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA 99: 11357–11362, 2002. 254. Zisman A, Peroni OD, Abel ED, Michael MD, MauvaisJarvis F, Lowell BB, Wojtaszewski JF, Hirshman MF, Virkamaki A, Goodyear LJ, Kahn CR, and Kahn BB. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 6: 924 –928, 2000. Downloaded from http://physrev.physiology.org/ by 10.220.32.247 on July 4, 2017 Physiol Rev • VOL 84 • APRIL 2004 • www.prv.org
© Copyright 2025 Paperzz